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2.1 Schematic representations of the GSEA-type and TSI-type algorithms
(A) The GSEA-type algorithm is depicted along with the two suggested permuta-
tion tests (red = permutation 1, blue = permutation 2). Details of the Lamb et al.
(2003) [39] study are included for illustration. (B) The TSI-type algorithm is de-
picted along with the suggested permutation test (red). Details of the Chang et al.
(2004) [10] Core Serum Response signature classification are included for illustration. 9
2.2 Heatmap of core serum response genes in each of the four data sets
considered. Red are serum induced samples, blue are serum independent samples,
and tan are unclassified samples. (A) Expression of 484 Unigene mapped core
serum response genes in the 50 in vitro samples of the primary experiment [10].
(B) Expression of the 376 core serum response genes in the 295 prostate tumor
samples [22] (C) Expression of the 421 core serum response genes in the 78 v’ant
Veer samples [67] (D) Expression of the 158 core serum response genes in the 86
Beer samples [4] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.3 In vitro samples and tumor samples are plotted for the first two dimen-
sions of Eigenspace. (A) 55% of the prostate tumor samples are classified: 78
as serum induced, 83 as serum independent (B) 69.3% of the breast tumor samples
are classified: 27 as serum induced, 27 as serum independent. (C) 48.9% of the
lung tumor samples are classified: 18 as serum induced, 24 as serum independent. . 19
2.4 Survival of tumor samples by classification. These plots demonstrate that
patients with samples in the serum induced class are likely to have a worse prog-
nosis. Both the classified and unclassified samples are included in these plots. The
log-rank statistic p-values from Kaplan Meier estimation are given for the sepa-
ration of the classes without and with inclusion of the unclassified samples in the
model (A) recurrence free survival in prostate cancer: p < 0.0001; p < 0.0001,
(B) recurrence free survival in breast cancer: p = 0.0207; p = 0.0078, (C) overall
survival in lung cancer: p = 0.0352; p = 0.0789 . . . . . . . . . . . . . . . . . . . . 20
2.5 The Cox regression test permutation results by percentage unclassified.
The Cox regression statistic is plotted against the percentage of unclassified samples
for each of the 1000 permutations. The circle filled in red denotes the original
classification. A test statistic listed as ‘NA’ indicates that there samples were
classified in only one class and thus no test statistic could be calculated. The
empirical p-value from the chi-squared statistics is depicted as a histogram in the
left margin. (A) Glinsky et al. (2004) [23] prostate tumor samples. P < 0.0001;
(B) van’t Veer et al. (2002) [67] breast tumor samples, p = 0.0783; (C) Beer et al.
(2002) [4] lung tumor samples, p = 0.0111. . . . . . . . . . . . . . . . . . . . . . . . 24
vii
2.6 Metabolite prediction by gene classifier Samples are plotted by their mapping
to the first two Eigenarrays either by their gene expression measures (circles) or
metabolite intensities (squares). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.7 Comparison of differential gene classifier to random sets The sunflower plot
adds one ‘petal’ for every observation and shows highest petal density around 50%
specificity and 50% sensitivity as expected for these 1000 randomly drawn sets.
The observed value is plotted with a red triangle. . . . . . . . . . . . . . . . . . . . 29
2.8 Histograms of (A) sensitivity and (B) specificty as achieved by random sets
of genes. P-values can be computed by a count of the random sets that are exceed
the observed value plotted in red. The observed sensitivity, 91.7%, has p = 0.001
and the observed specificity, 81.3%, has p = 0.006. . . . . . . . . . . . . . . . . . . 30
3.1 Type 1 error for per-metabolite tests using a significance threshold of α = 0.05
without multiple testing adjustments. 1000 datasets were simulated assuming
within pathway correlation of 0.2 for each metabolites and genes. Unweighted
(Raw) p-values and the five weight functions (A, −log10(p); B, |S|; C, |S̃|; D,
Φ(S̃ − µ̃); E, exp(S̃µ̃)) are depicted with increasing between element correlation,
ρGM ∈ (0, 0.1, 0.15). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.2 Type 1 error, under uniformly distributed differential elements, for per-
metabolite tests using a significance threshold of α = 0.05 without multiple testing
adjustments. 1000 datasets were simulated assuming within pathway correlation of
0.2 for each metabolites and genes and πGk = π
M
k = 0.1 for all k. Unweighted (Raw)
p-values and the five weight functions (A, −log10(p); B, |S|; C, |S̃|; D, Φ(S̃− µ̃); E,
e(S̃µ̃)) are depicted with increasing between element correlation, ρGM ∈ (0, 0.1, 0.15). 54
3.3 Type 1 error, under uniformly distributed differential elements, for per-
metabolite tests using a significance threshold of α = 0.05 without multiple testing
adjustments. 1000 datasets were simulated assuming within pathway correlation
of 0.6 for each metabolites and genes and πGk = π
M
k = 0.1 for all k. Unweighted
(Raw) p-values and the five weight functions (A, −log10(p); B, |S|; C, |S̃|; D,
Φ(S̃−µ̃); E, e(S̃µ̃)) are depicted with increasing between element correlation, ρGM ∈
(0, 0.1, 0.15, 0.25, 0.5). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 Power loss under uniformly distributed differential elements is depicted
by the average ROC curve for 1000 simulated datasets with πGk = π
M
k = 0.1 for all
k, ρGG = ρMM = 0.2, and ρGM = 0.1. . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.5 Average receiver operating characteristic (ROC) curves (n=100) depict the
sensitivity and specificity for each test method and weight function when applied
to per-metabolite tests. Data are simulated assuming within pathway correlation
of 0.2 for each metabolites and genes and between element correlation of 0.1. Ten
of fifty pathways were simulated as enriched where differential test statistics have
mean of two and three for metabolites and genes, respectively. The mean area
under the curve (AUC) estimate and associated standard error are provided in the
table below each plot. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
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3.6 Average receiver operating characteristic (ROC) curves (n=100) depict the
sensitivity and specificity for each test method and weight function when applied
to per-metabolite tests. Data are simulated assuming within pathway correlation
of 0.6 for each metabolites and genes and between element correlation of 0.15. Ten
of fifty pathways were simulated as enriched where differential test statistics have
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under the curve (AUC) estimate and associated standard error are provided in the
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3.7 Average receiver operating characteristic (ROC) curves (n=100) under the
same simulation conditions as in Figure 3.5 except that differential test statistics
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3.8 Average receiver operator characteristic (ROC) curves (n=100) assum-
ing µ̃ = 1. The CDF transformation (D, orange) and exponential (E, red) weight
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3.14 Scatterplot comparing weighted and unweighted p-values for each of the
147 mapped metabolties in the Sreekumar et al. (2009) [60] metabolite dataset.
The matched gene expression data were used to construct the weights. . . . . . . . 73
ix
4.1 Correlation of γ and µ (i) Correlation of the estimates of γ and µ do not differ
much from zero. (ii) They are under-dispersed compared to the expected normal
distribution under the Fisher’s z-score transformation. . . . . . . . . . . . . . . . . 89
4.2 Mahalanobis Distance (i) A contour plot overlaying the scatterplot of 100 ran-
dom draws from a bivariate normal distribution with mean zero, unit variance, and
50% correlation. The centroid defined by the marginal means is noted by a blue
square. Three points of interest are added as the red triangle, orange diamond and
purple circle (ii) The distribution of the Mahalanobis distance from the centroid
for each point in the scatter with the three new points highlighted. Their rank can
be used to determine a p-value. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
4.3 The symbol key for Figures 4.4 – 4.7. . . . . . . . . . . . . . . . . . . . . . . . . 102
4.4 Simulation results for 1000 genes and 200 metabolites generated for 30
samples. Seventy pathways are assumed with pathways 31–70 representing null
pathways. The correlation values are ρGG = ρMM = 0.20, and ρMG = 0.10. Four
metabolites and 20 genes are included in each pathway. The symbols represent the
frequency of rejecting the null hypothesis in 100 simulated datasets. The symbol
key can be found in Figure 4.3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.5 Simulation results for 1000 genes and 1000 metabolites generated for
30 samples. Seventy pathways are assumed with pathways 31–70 representing
null pathways. The correlation values are ρGG = ρMM = 0.20, and ρMG = 0.10.
Each pathway includes 20 metabolites and 20 genes. The symbols represent the
frequency of rejecting the null hypothesis in 100 simulated datasets. The symbol
key can be found in Figure 4.3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
4.6 Type I error associated with Figure 4.4. Each boxplot represents 100 mea-
surements of the error rate across the 41 null pathways. . . . . . . . . . . . . . . . 107
4.7 Type I error associated with Figure 4.5. Each boxplot represents 100 mea-
surements of the error rate across the 41 null pathways. . . . . . . . . . . . . . . . 107
4.8 The sum of the ranks of the 10 associated pathways assuming no differ-
ential elements were measured, that is d1 = d0 = c1 = c0 = 0. The correlation
structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of the 50 disjoint
pathway were simulated to contain 20 metabolites and 20 genes. Nsample = 30. . . 109
4.9 The sum of the ranks of the 10 associated pathways assuming a constant
probability of differential elements across the pathways measured, that is
d1 = d0 = c1 = c0 = 0.05. The correlation structure ρGG = ρMM = 0.20,
ρMG = 0.1 is assumed. Each of the 50 disjoint pathway were simulated to contain
20 metabolites and 20 genes. Nsample = 30. . . . . . . . . . . . . . . . . . . . . . . 110
4.10 The sum of the ranks of the 10 associated pathways assuming 25% of
the elements are differential in these pathways, that is d1 = c1 = 0.25 and
d0 = c0 = 0. The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed.
Each of the 50 disjoint pathway were simulated to contain 20 metabolites and 20
genes. Nsample = 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
x
4.11 The sum of the ranks of the 10 associated pathways assuming 25% of
the elements are differential in these pathways, that is d1 = c1 = 0.25 and
d0 = c0 = 0. The correlation structure ρGG = ρMM = 0.60, ρMG = 0.25 is
assumed. Each of the 50 disjoint pathway were simulated to contain 20 metabolites
and 20 genes. Nsample=30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
4.12 The sum of the ranks of the 10 associated pathways assuming 10% of
the elements are differential in these pathways, that is d1 = c1 = 0.10 and
d0 = c0 = 0. The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed.
Each of the 50 disjoint pathway were simulated to contain 20 metabolites and 20
genes. Nsample = 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.13 The sum of the ranks of the 10 associated pathways assuming 25% of
the elements are differential in these pathways, that is d1 = c1 = 0.25 and
5% of the elements are differential in the remaining pathways, d0 = c0 = 0.05.
The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of
the 50 disjoint pathway were simulated to contain 20 metabolites and 20 genes.
Nsample = 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.14 Venn diagrams comparing enrichment methods Panels i, ii, and iii compare
the univariate methods to each of the joint enrichment tests for the logistic regres-
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2.1 Genes are matched between gene expression array platforms using Uni-
gene ID numbers. For the permutation testing, all common genes between the in
vitro experiment [10] and each in vivo experiment were considered (prostate [23],
breast [67], lung [4], respectively). The classification of a set of in vivo samples
was done based on only the CSR genes identified in that data set. Permutation
sample size was determined based on the effective number of independent genes in
the CSR signature. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2 Cox regression results for the classified samples. Cox regression was run
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sensitivity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
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In the last decade the high-throughput assessment of gene expression, i.e. tran-
scriptomics, in a sample has grown to measure the whole genome with over 40,000
probes per microarray (e.g. Varambally et al. (2005) [68]). Microarray technology
uses complementary DNA fragments (Agilent Technologies, www.chem.agilent.com)
or oligonucleotide probes (Affymetrix, www.affymetrix.com) fixed on a slide to as-
sess mRNA abundance via the complementary binding of single-stranded nucleotide
sequences [49]. The reproducibility of the quantitative and qualitative assessment
has been demonstrated within platforms and, to a lesser extent, between platforms
[42]. Gene profiles resulting from gene expression analysis have even been translated
to clinical application (e.g. Wigelt et al. (2009) [72]).
An area of high-throughput analysis that has recently emerged is metabolomics,
the assessment of the small molecules in the sample [3, 25]. The data are generated by
mass spectrometry (MS) preceded by either gas or liquid chromatography (GC or LC)
[26, 69]. The initial chromatography step separates the molecules so that they can be
identified by their mass spectrum. When this separation step is skipped the metabolic
activity of the cell is measured as a metabolic fingerprint, but metabolites are not
measured individually [18]. In this work we consider all molecules under 10,000
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KDa. This includes such classes as amino acids, fatty acids, simple carbohydrates,
and exogenous drugs within the cell. Metabolomic studies currently detect between
one hundred and one thousand metabolites [21, 70, 60].
Small samples sizes and potentially high variance between samples can lead to low
power in the analysis of metabolomic intensity changes between human populations.
Specifically, the metabolome is affected by diurnal rhythms, diet, drugs and thera-
peutics, and other environmental factors beyond disease [38]. However, we know that
the global snapshot of any one molecular component is an isolated view of a larger
picture [31]. Thus we turn to data integration through systems biology to provide a
broader view of the disease while enhancing power and providing new insights.
This work has been motivated by a study of metabolomics in prostate cancer by
Sreekumar et al. (2009) [60]. Here 626 metabolites are detected across 42 prostate
tissue samples of increasing cancer severity; 16 benign adjacent prostate, 12 localized
prostate tumor, and 14 metastatic prostate tumors. Gene expression data were
also measured for 40 of these samples (excluding two metastatic samples); data
unpublished. Additionally, we consider another cancer progression dataset from the
the same group [68]; 4 benign adjacent prostate, 5 localized prostate tumor, and
4 metastatic prostate tumors. Though data are available for metastatic disease we
focus on the comparison of benign prostate and local prostate tumor tissues.
We integrate the data by mapping the two platforms to the metabolic pathways of
the Kyoto Encyclopedia of Genes and Genomes (KEGG) [35, 36, 34]. These pathways
represent the current literature for metabolomic biosynthesis and degredation. Genes
are mapped to the pathways via the enzymes with which they are associated. For
details on this mapping please refer to Appendix A.
In this dissertation we explore three analysis methods that are able to combine
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gene expression and metabolite intensity data. In Chapter II, we examine a classi-
fication method that allows us to utilize a differential list of elements from a prior
study to make prognostic or diagnostic predictions about samples in a current study.
A prognostic application is demonstrated using gene expression datasets of various
cancer samples. The method is then applied to the Sreekumar et al. (2009) [60]
metabolite data using a gene profile from the Sreekumar-matched gene expression
data to build the classifier. In Chapter III, we explore the power gain available to
per-metabolite tests of differential intensity when the tests are weighted according
to a per-pathway ranking constructed from the gene expression data. We summarize
the information in the gene expression data using set enrichment scores on the KEGG
pathways. The methods are explored through two simulation models; one simplistic
and one motivated by the Varabmally et al. (2005) [68] gene expression data and
the Sreekumar et al. (2009) [60] metabolite data. Chapter IV considers the joint
enrichment testing of differential results from the metabolomic and gene expression
datasets. We extend two different set enchriment tests to allow multi-dimensional in-
put. Through simulation we compare these methods to their univariate counterparts,
the Fisher’s exact test, and to two simple meta-analysis approaches. An additional
statistical goal of this dissertation is to define the null hypothesis under considera-
tion in each test so that appropriate testing measures can be defined. This will be
discussed for each chapter in turn.
CHAPTER II
Statistical issues and analyses of in vivo and in vitro
genomic data in order to identify clinically relevant profiles
Integration of in vitro studies, i.e. experimental studies, with human “in vivo”
gene expression studies is an area that is being considered more frequently in the
functional genomic analysis of cancer. Hypotheses about cancer development, pro-
gression, and risk factors are difficult to test directly in a patient population. How-
ever, in experimental studies on tissue cultures and model organisms, conditions can
be specifically controlled to allow biological hypotheses to be tested. Integrating the
results from such controlled experiments with in vivo cancer signatures holds the
potential to both infer activity of specific oncogenic pathways in vivo and to identify
relevant effectors of oncogenic pathways.
This biologically directed analysis of two gene expression data sets holds potential
for the integration of omics data. Consider that transcriptomic studies are more
readily available and currently more robust than metabolomic studies. Thus, we can
use transcriptomic data in place of the controlled in vitro studies and metabolomic
data in place of the in vivo data. We explore the ability to use this methodology
to use gene expression data to make predictions about the metabolomic profiles of
tumor tissues.
We begin with a description of the integration task at hand and a review of recent
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work in in vitro and in vivo integration. We outline an approach for quantifying the
predictive ability of a gene expression profile determined from an in vitro experiment
based on the tissue similarity approach of Sandberg and Ernberg (2005) [56]. We
describe the application of the proposed methodology using in vitro data from a
wound healing study conducted by Chang et al. (2004) [10] and in vivo data from
Glinsky et al. (2004) [23], van’t Veer et al. (2002) [67], and Beer et al. (2002) [4]. We
follow-up with the integration of the Sreekumar et al. (2009) [60] metabolomic data
and matched gene expression data (unpublished).
2.1 Integrating in vitro and in vivo studies
To understand the mechanisms by which oncogenes cause cancer, studies have
used gene-expression profiling to identify downstream targets of oncogenic pathways
in cell-culture systems. Conceptually, this involves manipulating a gene in an in
vitro system, measuring the global profile using gene expression technology and then
trying to relate the in vitro gene expression profile to an in vivo gene expression
profile. Such an approach was taken by Lamb et al. (2003) [39] to determine the
direct transcriptional effects of the oncogene Cyclin D1. In vitro experiments were
performed in which the Cyclin D1 was both over and under expressed, and global
gene expression profiles were determined. Lamb et al. (2003) [39] found that there
was a significant correlation between the targets found in vitro and the ordered gene
list in a human tumor dataset thus suggesting the role of Cyclin D1 regulation in
tumorigenisis. Another example of in vitro/in vivo gene expression data integration
appears in the study of Huang et al. (2003) [32]. They developed distinct in vitro
oncogenic signatures for three transcription factors: Myc, Ras and E2F1-3. These
signatures were able to predict the Myc and Ras state in mammary tumors that
6
developed in transgenic mice expressing either Myc or Ras, suggesting that specific
oncogenic events are encoded in global gene-expression profiles.
Additionally, studies have used gene-expression profiling of cancerous growths in-
duced in model organisms to examine tumor development or progression. Though
model organism studies have the added difficulty of mapping orthologous genes be-
tween organisms, a difficulty not shared with tissue and cell cultures of human origin,
there have been promising applications. For example, Sweet-Cordero et al. (2005)
[62] defined a KRAS induced lung cancer signature by comparing lung tumors gener-
ated from a spontaneous KRAS mutation mouse model to normal mouse lung tissue.
They then correlated this KRAS lung cancer signature with gene expression profiles
in human lung cancer studies and found that the mouse signature shared significant
similarity with human lung adenocarcinoma but not with other lung cancer types.
Next, Sweet-Cordero et al. (2005) [62] looked for evidence of the KRAS signature
in human tumors carrying activating KRAS mutations relative to wild-type tumors.
Although no individual genes were significantly associated with the KRAS muta-
tion status in human tumors, the mouse KRAS signature was significantly enriched
among genes rank-ordered by differential expression in human tumors with a KRAS
mutation.
2.1.1 Background and Review
One class of methods that has been popular in the literature for in vitro/in vivo
genomic data analysis is the following. First, one generates ordered lists of genes
using the in vivo expression data. One then generates a differentially expressed gene
list using the in vitro data and studies the overlap between the two lists. The seminal
examples of this are in Mootha et al. (2003) [44] and Lamb et al. (2003) [39], which
were then used as the basis of the Gene Set Enrichment Analysis (GSEA) method
7
[61]. We describe the GSEA methodology by briefly reviewing what was done in the
Lamb et al. (2003) [39] study.
First, a list of differentially expressed genes was generated based on the compar-
ison of Cyclin D1 overexpressing relative to wildtype (no Cyclin D1 manipulation)
mammary epithelial cell lines. Next, each gene’s expression in vivo, from 190 human
tumor samples of various origins, was correlated to that of Cyclin D1 and the genes
were ranked accordingly. Then, a Kolmogorov-Smirnov (KS) statistic was used to
determine if the in vitro differential expression list clustered within the correlation-
ordered in vivo list. Since there was significant evidence of clustering, Lamb et al.
(2003) [39] determined that the in vitro-defined targets of Cyclin D1 were correlated
with their respective levels in vivo. This suggests that the direct regulatory effects
of Cyclin D1 may play an important role in tumorigenesis.
There are some desirable features of the GSEA method. First, it utilizes all the
information available in the in vivo gene expression data; no thresholding is done
in that dataset. Second, a Kolmogorov-Smirnov statistic is used for the analysis,
which is a nonparametric method and thus provides some robustness. However,
there are several disadvantages to GSEA as well. For instance, note that there is
thresholding done in the in vitro gene expression dataset to select the differentially
expressed gene set. A potential improvement to the GSEA method, to avoid this
thresholding, would be the following. First, one determines the common genes in
the in vivo and in vitro datasets. One then takes the scores of differential expression
from the in vitro data, finds the corresponding correlation scores (correlation with
Cyclin D1) in the in vivo data and examines a scatterplot of the two variables. If
the association is linear, then one tests for association using the Pearson correlation
coefficient between the two variables. If instead the association appears nonlinear,
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then one could use a smoothing-spline based test [40]. Such an approach would
give a direct test of association between the correlations in vivo and the differential
expression measurement in vitro without requiring thresholding of any datasets and
would still allow for a nonlinear relationship between the two variables.
Before going further, let us consider the null hypothesis under consideration in
the GSEA method, or the variants proposed above. Specifically, in the Lamb et al.
(2003) [39] study they test:
H0: There is no association between differential expression of Cy-
clin D1-overexpressed, relative to non-overexpressed, cell lines and
correlation with Cyclin D1 in human tumors.
The alternative hypothesis is that there is an association. In specifying the null
hypothesis we uncover a more subtle disadvantage of the GSEA method - the deter-
mination of the distribution of the KS test statistic under the null hypothesis.
Two variants of permutation testing have been proposed by Subramanian et al.
(2005) [61] to elucidate the distribution of the KS test statistic assuming the null
hypothesis is true. In the first, the sample labels in the in vitro data are permuted,
the differentially expressed gene signature is redefined, and the Kolmogorov-Smirnov
statistic is recomputed based on this new signature; see Figure 2.1A, red. Here the
implication is that the correlation between the two Cyclin D1 levels in the cell line
experiment is removed by the permutation. However, this addresses the differential
expression in the in vitro samples but does not address a null association with the
in vivo samples. In the second version, the sample labels in the in vitro and in vivo
datasets are permuted, both the in vitro differential expression signature and the in
vivo correlations are redefined, and the Kolmogorov-Smirnov statistic is recomputed;
see Figure 2.1A, blue. Again, the implication is to remove the association within the
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Figure 2.1: Schematic representations of the GSEA-type and TSI-type algorithms (A)
The GSEA-type algorithm is depicted along with the two suggested permutation tests
(red = permutation 1, blue = permutation 2). Details of the Lamb et al. (2003) [39]
study are included for illustration. (B) The TSI-type algorithm is depicted along with
the suggested permutation test (red). Details of the Chang et al. (2004) [10] Core Serum
Response signature classification are included for illustration.
in vitro and in vivo experiments. Yet this permutation scheme still does not address
the association between the in vitro differential expression and the in vivo correlation.
The role of permutation testing is to simulate the distribution of the test statistic
assuming that H0 is true; however, the two permutation schemes developed in the
GSEA method do not do this. Permutation of the sample labels fails because the null
hypothesis pertains to the population of genes in the two studies and not the relation
of samples within a study. Additionally, Shedden (2004) [58] suggests that permuting
the sample labels of both the in vitro and in vivo data sets is not appropriate.
Simply, if the permutation does not correctly model the null hypothesis, then we are
answering a different question than the one asked.
There is an alternative approach to the GSEA method for integrative analysis of
in vitro and in vivo data, the implementation of which is the focus of this chapter.
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It is based on ideas of classification and clustering since the goal in many genomic
studies utilizing high-throughput expression technologies is to develop a signature
that can discriminate between relevant classes or groups of samples. In general,
demonstration of the predictive or prognostic ability of a classification signature
on independent data sets is a crucial step in the validation of that signature [52].
Thus, differential expression signatures discovered in vitro are often “validated” on
independent in vivo data sets, such that the in vitro data is the training dataset and
the in vivo data is the testing dataset. In this validation setting, the null hypothesis
that we wish to test is the following:
Hclass0 : There exists no set of genes derived from the in vitro gene
expression that can predict clinical outcome in the in vivo expression
data.
The alternative is that at least one set of genes derived from the in vitro data is
predictive. Notice that this null hypothesis is different from the null hypothesis de-
scribed for the GSEA method. For clarity, we will refer to Hclass0 as the classification
null hypothesis.
An advantage of the classification null hypothesis is that permutation testing
becomes possible here. In particular if Hclass0 is true, then any set of genes derived
from the in vitro expression profile data will have no ability to separate samples in
the in vivo expression dataset with regard to a clinical outcome. Thus, we can take
random sets of genes from the in vitro data and apply the classification algorithm of
interest. If the classification null hypothesis is true, then all sets of genes, including
the derived signature, should provide equal prediction performance.
The classification null hypothesis has motivated the following algorithm that we
have used in our previous work [68]. Here we are considering the genes common to
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the in vitro and in vivo expression datasets.
1. Derive a gene signature (i.e. interesting gene list) from the in vitro gene expres-
sion data;
2. Select those genes from the in vivo expression data that are included in the in
vitro signature and cluster the samples from the in vivo expression data into
two groups using hierarchical clustering with average linkage clustering and
Euclidean distance;
3. Calculate the log-rank statistic for survival between the two groups of patients;
4. Let L denote the size of the gene list in 1. Randomly choose L genes from the
in vitro data as the gene signature. Continue with steps 2 and 3 above.
5. Repeat steps 2-4 1000 times. Calculate the proportion of datasets in which the
log-rank statistic is greater than the one calculated initially from the signature
in step 1.
The proportion calculated in step 5 will be the permutation p-value under the
classification null hypothesis. This permutation scheme will form the basis of as-
sessing significance for our proposed analytical scheme described in the next section.
We note that one could also modify the GSEA procedure in a similar way, as shown
in Lamb et al. (2003) [39], such that we randomly draw the gene set from the in
vitro data rather than assessing differential expression based on permuted sample
labels. Unfortunately, Shedden (2004) [58] shows that when one does not account
for gene-gene correlation, the resulting test statistic can be too liberal by as much
as 10 times.
Notice that a limitation of the classification null hypothesis is that the alternative
hypothesis states that there exists at least one signature from the in vitro expression
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data that is predictive in the in vivo expression data. In fact the experimentally
derived gene list need not be a unique classifier. It has been recently noted that
there are likely many gene signatures that have similar predictive power [14, 15]. It
may be due in part to genetic redundancy or to the high correlation of genes within
a pathway. Yet if the in vitro gene signature is able to predict prognosis better
than a randomly selected set of genes we expect that there is biological significance
to that signature. Thus permutation testing helps us to determine if the gene set
derived from the in vitro experiments is of interest for further study of its biological
relevance.
2.1.2 Proposed methodology for in vitro/in vivo analyses
The paper of Sandberg and Ernberg (2005) [56] considers the relationship between
the gene expression of in vitro cell cultures and their respective in vivo tumor samples.
To that end they developed an algorithm for comparing gene expression values across
experiments that they call the tissue similarity index (TSI). We use that algorithm
here to compare the in vivo tumor samples to the in vitro samples of a lab experiment.
The algorithm of Sandberg and Ernberg (2005) [56] is as follows; see Figure 2.1B.
Principal component analysis is run on the covariance matrix of gene expression for
genes in the in vitro dataset. Data are scaled across arrays so that each gene has a
mean expression of zero and a unit standard deviation. The resulting Eigenarrays
(Eigenvectors) are stored. To project the in vitro gene expression into the reduced
dimensional space, created by the Eigenarrays, calculate the correlation between
each Eigenarray and each in vitro sample array. The consensus signature for each
experimental condition (serum induced and serum independent) is represented by its
median centroid in the reduced space.
To integrate the in vivo data, first map the in vivo samples into the same reduced
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space of the in vitro samples by again calculating the correlation between each Eige-
narray and in vivo sample array. To maintain scale in this correlation, the tumor
samples are also standardized so that each gene has a mean expression of zero and
a unit standard deviation. The distance between the in vivo tumor sample and each
of the two consensus signatures, ie centroids, is calculated using Pearson correla-
tion. Samples are classified with the experimental condition with whose centroid
they correlate best.
There are several differences between their and our implementations of TSI. First,
in contrast to Sandberg and Ernberg (2005) [56], we use positive statistical signifi-
cance of the TSI to determine classification, thus allowing some samples to remain
unclassified. In their paper they used an ad-hoc threshold value for TSI score, delin-
eating moderate and high correlation groups. It is natural to believe that some of the
in vivo samples will not correlate well with the in vitro conditions. These unclassified
samples may actually be informative in that they define a subset of cases which do
not meet our expectation as developed in the hypotheses tested in vitro. Second, the
goal of the Sandberg and Ernberg (2005) [56] paper was qualitative assessment of
cell line gene expression relative to in vivo tumor gene expression, thus they do not
address the issue of statistical significance of their method. However, the classifica-
tion provided by the TSI can be tested for prognostic or diagnostic value depending
upon the study goal.
Since the gene signature on which the classification is based is determined from
the in vitro data, and does not use the in vivo data, the statistical significance of any
tests on the in vivo data can be accepted without bias. This is an example of using
the in vitro data for the training dataset and the in vivo data for the testing dataset.
Indeed, if this in vivo validation is not marginally significant it is not of interest to
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proceed further to test the classification null hypothesis.
Here the TSI method develops a classification scheme from the in vitro signature.
The null hypothesis of interest is again the classification null hypothesis as presented
above. We thus propose the use of a permutation test to determine the utility of
the gene signature in its classification ability. In the following we slightly modify
the permutation test procedure described in the previous section to account for
gene-gene correlation within the in vitro gene signature. Specifically, as it is likely
that genes within a pathway are correlated, it is reasonable to assume that the
significantly differentially expressed genes that comprise the in vitro signature are
correlated. Shedden (2004) [58] showed that this correlation can lead to liberal p-
values. Additionally, in the classical genetics setting, Nyholt (2004) [50] shows that
permutation tests that do not account for this correlation can be misleading and
proposes a simple adjustment. In essence, rather than randomly selecting L genes
in each cycle of the permutation test, only M (M < L) genes are selected, where M
is calculated to be the effective number of independent genes in the gene signature
[50]; see Figure 2.1B.
Finally, the permutation test for the TSI analysis has two interesting attributes
against which the classification signature is compared. Specifically, in permuting
the data, the TSI scores are recalculated using the randomly selected gene list and
with each randomly selected set of genes there is a possibility of unclassified samples.
Thus the classification is compared to: (1) the measure of association with predictive
factors in vivo, and (2) the percentage of unclassified samples in vivo.
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2.2 Gene expression data acquisition and preparation
For the purpose of demonstration we use, as the in vitro derived signature, the
wound healing signature of Chang et al. (2004) [10]. Derived from cultured fibroblasts
in the presence and absence of serum components, the wound healing signature is
composed of 573 genes that are differentially expressed in response to serum. We
consider the wound healing signature, or Core Serum Response (CSR), as the in
vitro basis of classification of in vivo tumor samples - prostate tumor samples [23],
breast tumor samples [67], and lung tumor samples [4] - into good and bad prognosis
groups.
The fibroblast gene expression data [10] were downloaded from the Stanford Mi-
croarray Database (SMD, http://smd.stanford.edu/cgi-bin/publication/
viewPublication.pl?pub_no=293) (platform: cDNA microarray, 50 samples). The
data were normalized using loess normalization by print block within array [74].
Inter-array variability was accounted for by scaling using the MAD (median absolute
deviation). Missing data were imputed using KNN (K-nearest neighbors) imputation
as implemented in the pam.r package [27, 65].
Localized prostate tumor probe-set level expression measures and recurrence free
survival information [23] were obtained from the Sidney Kimmel Cancer Center web-
site (no longer posted at time of submission) (platform: Affymetrix U95Av2, 295
samples). Lung adenocarcinoma probe-set level expression measures and overall sur-
vival information [4] were obtained from http://dot.ped.med.umich.edu:2000/
pub/Lung/index.html (platform: Affymetrix HUgenFL, 86 samples). Sporadic
breast cancer expression data and recurrence free survival information [67] were ob-
tained from http://www.rii.com/publications/2002/vantveer.html (platform:
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Table 2.1: Genes are matched between gene expression array platforms using Unigene
ID numbers. For the permutation testing, all common genes between the in vitro
experiment [10] and each in vivo experiment were considered (prostate [23], breast [67],
lung [4], respectively). The classification of a set of in vivo samples was done based on
only the CSR genes identified in that data set. Permutation sample size was determined
based on the effective number of independent genes in the CSR signature.
Unigene maped Genes Unigene Effective number
genes per common with mapped of independent
Samples microarray in vitro samples CSR genes genes
In Vitro 20414 - 484 -
Prostate Cancer 11772 9753 367 345
Breast Cancer 17168 13600 421 399
Lung Cancer 4705 3891 158 136
Aglient Hu25K, 78 samples). Each of these experiments was normalized by global
scaling per array. No imputation was done for missing data in the tumor sample
data sets.
Unigene Cluster ID number was used to map genes between platforms. Annota-
tion information was acquired from SOURCE [12]. If, for a given platform, multiple
measurements were represented by the same Unigene Cluster ID, these expression val-
ues were averaged within array, thus allowing one-to-one mapping of genes between
platforms. Genes were mapped to Unigene Cluster ID from GenBank Accession
number if available [10, 23, 67] or from Unigene Symbol [4].
2.3 Application of the TSI based classifier
The classifier was built using the CSR in vitro signature and the TSI algorithm,
described in the previous section and in Figure 2.1B. The classifier was built for
each of the three in vivo experiments using only those genes in the CSR signature
that were common to both the in vivo and in vitro experiments; see Table 2.1 and
Figure 2.2. All 50 Eigenarrays were used for the TSI classification algorithm and
classification is based on significant positive correlation with one of the two CSR
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A B C D
Figure 2.2: Heatmap of core serum response genes in each of the four data sets consid-
ered. Red are serum induced samples, blue are serum independent samples, and tan
are unclassified samples. (A) Expression of 484 Unigene mapped core serum response
genes in the 50 in vitro samples of the primary experiment [10]. (B) Expression of the
376 core serum response genes in the 295 prostate tumor samples [22] (C) Expression
of the 421 core serum response genes in the 78 v’ant Veer samples [67] (D) Expression
of the 158 core serum response genes in the 86 Beer samples [4]
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group centroids. Figure 2.3 plots the first two dimensions of this reduced space for
each of the three tumor types. The cell cultures that were grown in the presence
of serum were considered to be serum induced, whereas those grown without serum
components were serum independent. In vivo samples that correlate significantly
(p < 0.05) with the composite serum induced signature, ie centroid, are classified
as serum induced. Likewise, those in vivo samples correlating significantly with the
centroid of the serum independent samples are labeled serum independent. In vivo
samples that do not correlate significantly with either centroid remain unclassified.
In Figure 2.3, the tumor samples are colored according their classification and the
in vitro samples and centroids are included for reference.
According to Hclass0 , we wish to see if the in vitro derived CSR signature has
prognostic ability in vivo. Thus the prognostic ability of the CSR signature as a
classifier was tested using univariate Cox regression; see Table 2.2. The TSI score
was incorporated through its discrete classification of the in vivo samples, as de-
scribed above. Figure 2.4 contains the Kaplan-Meier survival curves for this discrete
classification. The red and blue curves represent the serum activated and serum
independent classifications, respectively. Log rank statistics on the Kaplan-Meier
estimates indicate that there is a significant separation between the curves for the
prostate tumors (p < 0.0001), the breast tumors (p = 0.0207), and the lung tumors
(p = 0.0352). The tan curve shows the survival of those samples that did not signif-
icantly correlate with either the serum activated or serum independent profiles and
are thus left unclassified by the TSI algorithm. When this unclassified group was
included in the Log-rank test of survival curve separation the prostate cancer and
breast cancer samples remained significant (p < 0.0001 and p = 0.0078, respectively)
whereas the lung cancer samples were marginally significant (p = 0.0789).
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Figure 2.3: In vitro samples and tumor samples are plotted for the first two dimensions
of Eigenspace. (A) 55% of the prostate tumor samples are classified: 78 as serum
induced, 83 as serum independent (B) 69.3% of the breast tumor samples are classified:
27 as serum induced, 27 as serum independent. (C) 48.9% of the lung tumor samples
are classified: 18 as serum induced, 24 as serum independent.
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Figure 2.4: Survival of tumor samples by classification. These plots demonstrate that patients
with samples in the serum induced class are likely to have a worse prognosis. Both the
classified and unclassified samples are included in these plots. The log-rank statistic p-
values from Kaplan Meier estimation are given for the separation of the classes without
and with inclusion of the unclassified samples in the model (A) recurrence free survival
in prostate cancer: p < 0.0001; p < 0.0001, (B) recurrence free survival in breast cancer:
p = 0.0207; p = 0.0078, (C) overall survival in lung cancer: p = 0.0352; p = 0.0789
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Table 2.2: Cox regression results for the classified samples. Cox regression was run on the
samples that were classified as serum induced or serum independent by the CSR gene
signature. Unclassified samples are excluded from this analysis. The hazard ratios are
relative to the serum independent classification.
Number Classified
Serum Serum Percent Hazard χ2 Test Empirical
Samples Induced Independent Unclassified Ratio Statistic p-value p-value
Prostate 78 83 45.4% 3.35 20.9 <0.0001 0.0040
Breast 27 27 30.8% 2.96 4.80 0.0284 0.0783
Lung 18 24 51.2% 3.40 3.94 0.0471 0.0111
As depicted in Figure 2.2, the simple dichotomization of in vivo samples by hi-
erarchical clustering is far from optimal. By the nature of hierarchical clustering,
dichotomization can be achieved by splitting samples at the first node. In Figure 2.2
we have color coded the samples by their TSI predicted classification (red = serum
activated, blue = serum independent, tan = unclassified) and we see that there is het-
erogeneity in the classification suggested by dichotomization at the first node of the
dendrogram. This heterogeneity is apparent in the Kaplan Meier plots of Figure 2.4.
Notice that the prostate samples appear to be least heterogeneous, see Fig-
ure 2.2B, in that most of the serum activated samples are clustered on the left
and most of the serum independent samples are clustered on the right with the
unclassified samples interspersed among both branches. The Kaplan Meier plot in
Figure 2.4A suggests that those samples which can be classified by their serum re-
sponse have the best and worst recurrence free survival with the unclassified samples
having intermediate recurrence free survival. The intermediate nature of the unclas-
sified samples may be due to a third class of tumors with moderate serum response or
it may be due to a blending of high risk and low risk samples that were not separated
by the CSR signature.
The breast cancer samples appear to be have a more well defined subset of un-
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classified samples, see Figure 2.2C. The far right branch of the dendrogram (as split
on the second node) contains a high percentage of unclassified samples. In the Fig-
ure 2.4B, the unclassified samples are associated with a recurrence free survival curve
that is worse than for the serum activated samples. In the lung cancer data it is not
clear that classification on any of the first three nodes of the dendrogram would
result in homogeneous classification based on the CSR signature; see Figure 2.2D.
However, using the TSI classification we are able to significantly split the samples
into good and bad prognosis groups based on overall survival; see Figure 2.4C.
2.3.1 Permutation testing of Hclass0
Accepting the above significant separation of the Kaplan-Meier curves as valida-
tion of the CSR signature in vivo, we proceed to test the classification null hypothesis
using 1000 random samples from the genes in common between the in vivo and in
vitro samples, see Table 2.1. The size of the randomly drawn set of genes was deter-
mined by the correlation in the original CSR genes, such that the randomly drawn
sets contained an equivalent number of effectively independent genes as the CSR set.
The TSI score was recalculated on each of these 1000 random gene sets. It was then
used to classify the in vivo samples and predict survival.
Figure 2.5 depicts the classification and prediction ability of the 1000 random
sets for each of the three in vivo data sets. The CSR gene predictor is colored red
in these plots. The vertical axis plots the predictive ability of the gene set as the
chi-squared test statistic associated with univariate Cox regression on the classifier.
If we look at the vertical margin we arrive at the permutation p-value as depicted by
the marginal histogram. However, we have additional information about the utility
of the CSR signature as a classifier. The horizontal axis provides the percentage of
the samples that remained unclassified in each of the 1000 random sets. In each
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case, the classifier based on the CSR genes has a lower percentage of unclassified
samples than any of the randomly drawn gene sets. Finally, note that for some of
the randomly drawn gene sets, see Figures 2.5B and 2.5C, the samples were classified
into only one group and thus the chi-squared test statistic could not be calculated.
This occurred when the percentage of unclassified samples was high.
The three plots of Figure 2.5 carry a lot of interesting information regarding the
utility of the CSR gene signature as a predictor of survival among the three tumor
types. First, consider the horizontal axes of Figures 2.5A-C. It is intriguing that for
all three tumor types the CSR signature has the lowest percentage of unclassified
samples. Yet we see that percentage of classified samples is not the sole predictor of
significant separation in the survival curves since there are randomly selected gene
sets that have higher percentages of unclassified samples but also have higher test
statistics.
Next, consider the empirical p-value for testing Hclass0 . In the prostate samples,
Figure 2.5A, the empirical p-value is 0.0040, whereas the p-value obtained from
a simple training/testing strategy is very small (chi-squared test statistic = 20.89,
p < 0.0001). In fact from the scale on the vertical axis we see that most of the random
permutation samples were able to predict a significant separation in the survival
of the prostate cancer patients. Thus had we relied only on the training/testing
strategy we could not distinguish that the CSR signature is superior to 99.6% of
the randomly selected signatures. The range of scale of the test statistics for the
breast cancer and lung cancer samples are less dramatic. In fact the empirical p-
value for the lung cancer dataset behaves we would normally expect, showing that
a minimally significant test statistic in the training/testing setting (p = 0.0352) is





Figure 2.5: The Cox regression test permutation results by percentage unclassified. The
Cox regression statistic is plotted against the percentage of unclassified samples for each
of the 1000 permutations. The circle filled in red denotes the original classification. A
test statistic listed as ‘NA’ indicates that there samples were classified in only one
class and thus no test statistic could be calculated. The empirical p-value from the
chi-squared statistics is depicted as a histogram in the left margin. (A) Glinsky et al.
(2004) [23] prostate tumor samples. P < 0.0001; (B) van’t Veer et al. (2002) [67] breast
tumor samples, p = 0.0783; (C) Beer et al. (2002) [4] lung tumor samples, p = 0.0111.
25
(empirical p = 0.0111).
2.3.2 Differences in array configurations may reduce utility of the in vitro signature
One problem encountered in this analysis was the integration of gene expression
data across microarray platforms. We attempted to compensate for this numeri-
cally by global standardization that centered the array-wise median values at zero.
Furthermore, in the TSI algorithm genes were standardized to zero mean and unit
standard deviation before being mapped into the reduced space. An additional com-
plication, beyond numerical scaling, is that the differing array configurations between
the in vitro and in vivo experiments mean that only those genes with Unigene ID
numbers common to both data sets can be considered. This initially excludes ESTs
from the in vitro signature as well as other features that do not have Unigene ID
numbers. The signature is further reduced by focusing on only the common genes
between data sets as determined by Unigene ID. We expect that there is correlation
between the genes within the CSR signature and thus the loss of some genes from
this signature will be tolerable.
The most dramatic decrease in CSR genes available for the analysis was for the
Beer et al. (2002) [4] lung samples which measured only 32.6% of the 484 Unigene
mapped CSR genes; see Table 2.1. It is possible that the high observed percentage
of unclassified samples, 51.2%, is related to this diminished in vitro signature. Also,
notice that in Figure 2.3C, that the mapping of the in vitro samples into the reduced
space appears to have flipped about horizontal axis from what we saw for the other
two in vivo data sets. Since the reduced space is determined by the in vitro data we
expect that this inversion is a result of the diminished in vitro signature. However,
this inversion does not affect the association of the classification with prognosis. As
shown in Figure 2.4C the serum induced class has worse overall survival than the
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serum independent class, as expected. This change in the reduced space mapping
highlights the necessity to calculate the TSI classifier independently for each in vivo
dataset, or particularly for each different array platform and configuration used by
the in vivo experiments.
2.4 Application of the TSI based classifier to integrate gene expression
and metabolomic data
In the interest of data integration between transcriptomics and metabolomics we
applied this classification method to these data. Specifically we used the Sreekumar-
matched gene expression data to build the TSI classifier for benign versus cancer
samples. We then used this classifier to predict the sample diagnosis of the Sreekumar
et al. (2009) [60] metabolomics data.
Integrating these data sources for this purpose requires a means of mapping the
genes and metabolites. We used enzymes as the common variable for genes and
metabolites, obtaining this information from the Kyoto Encyclopedia of Genes and
Genomes (KEGG, version 50) [35, 36, 34]. That is the genes whose products compose
an enzyme were matched to the metabolites on which the enzyme acted. This resulted
in between 1 and 205 gene probes from the Agilent Whole Human Genome microarray
mapped per metabolite. There were 133 metabolites that mapped to at least one
enzyme. We reduced the list of genes to a 1:m mapping by selecting the gene probe
with the maximum variation across the samples for each metabolite. It is not a 1:1
mapping because multiple metabolites are associated with only a single gene. The
duplication was as much as 6 for one gene but the mapping was 1:1 for a majority of
the metabolites. Duplications in the data may cause stability issues in the principal
components analysis but did not appear to cause problems in this analysis.
We were also concerned that the metabolomic data is measured by mass spec-
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trometry, and thus will have a dynamic range different from data collected by gene
expression microarray. As for the differing microarray platforms used in the above
work, we standardized each gene and metabolite to have a mean expression of zero
and a unit standard deviation.
In the above work we used the CSR gene list to build the classifier. Here we used
the set of genes that were differential (p ≤ 0.05) by a two-sided two-sample Welch’s
t-test between benign and local cancer samples (n=16 and 12, repectively). This set
has 39 genes mapping to 43 metabolites. Interestingly when the set size is corrected
for correlation the effective sample size is estimated at 38 genes.
The TSI classifier is built using the 39 differential genes and then applied to the
metabolite data. We see in Figure 2.6 that the first two principal components do
well separating the two diagnostic classes. For the classification of the metabolites
we use the first three principal components. The choice to use three components
was made a priori but post hoc analysis finds that this may be an optimal choice.
Classification was made by the absolute TSI score, that is the sample is classified
with the centroid with which it correlates best. Requiring a significant correlation
did not result in any samples being classified.
The classification of the metabolomic samples resulted in 91.7% sensitivity and
81.3% sensitivity; see Table 2.3. The one undetected cancer sample has a Gleason
grade of 3+4 so it is of moderate severity, however, this patient also contributed
an adjacent benign sample. Of the three misdiagnosed benign samples, one was
contributed by a patient who also contributed a moderate (4+3) cancer sample and
a high grade (4+4) cancer sample. No information was available regarding the tumor
grade of patients contributing the other two misclassified bengin samples.

























































Figure 2.6: Metabolite prediction by gene classifier Samples are plotted by their mapping to
the first two Eigenarrays either by their gene expression measures (circles) or metabolite
intensities (squares).
Table 2.3: Classification of metabolomic samples The first three prinicpal components were
used to generate a classifier from the differentially expressed genes. This classifier pre-
dicted the metabolite sample dianosis with 91.7% sensitivity and 81.3% sensitivity.
Classification
Diagnosis Benign Cancer Total
Benign 13 3 16
Cancer 1 11 12
Total 14 14 28
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Figure 2.7: Comparison of differential gene classifier to random sets The sunflower plot
adds one ‘petal’ for every observation and shows highest petal density around 50%
specificity and 50% sensitivity as expected for these 1000 randomly drawn sets. The
observed value is plotted with a red triangle.
null hypothesis. Here we are interested in the sensitivity and specificity obtained by
the classifier. For this integrative analysis we can write Hclass0 : There exists no set
of genes derived from the in gene expression data that can predict diagnosis in the
metabolite intensity data. To test this null hypothesis we generate 1000 random sets
of 43 genes from the 133 gene set and compare their classification ability to that of
our differential gene list. We did not adjust for the correlated data by drawing the
effective sample size of 38 genes since there is likely to be correlation in any randomly




























Figure 2.8: Histograms of (A) sensitivity and (B) specificty as achieved by random sets of
genes. P-values can be computed by a count of the random sets that are exceed the
observed value plotted in red. The observed sensitivity, 91.7%, has p = 0.001 and the
observed specificity, 81.3%, has p = 0.006.
Figure 2.7 shows that a majority of the 1000 randomly drawn sets have sensitivity
and specificity around 50% as expected. We can marginally assess how likely it is
that a random set would meet or exceed the sensitivity and specificity seen by the
original differential gene set. One set achieves the same sensitivity; a p-value of
0.001. There are 5 sets that achieve and one set that exceeds the observed specificty;
a p-value of 0.006. No random sets achieve the same levels of both sensitivity and
specificity. The marginal results can also be seen in the histograms in Figures 2.8 i
and ii, respectively.
The low p-values recommend that we reject the null hypothesis Hclass0 . This
means that there is at least one set of genes that can predict the diagnosis of the
metabolite samples. Caution should be exercised however since the gene expression
and metabolite intensity data were measured from the same set of 40 samples. This
is an ideal situation and classification may be more difficult for data from different
samples or from different labs. However, these results show give evidence that gene
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expression data can be used to make predictions in metabolite data.
CHAPTER III
Pathway-directed weighted testing procedures for the
integrative analysis of gene expression and metabolomic data
3.1 Introduction
Currently we are experiencing an explosion of high-throughput technology for
assessing global snap-shots of the molecular behavior of cells. Global assays exist
for measuring DNA sequence and copy number, mRNA transcript levels, protein
presence and abundance, as well as metabolite abundance in biological samples of
healthy and diseased tissues [43].
Transcriptomics is the high-throughput study of the transcriptome, the cellular
complement of gene transcripts. Gene expression microarrays use complementary
DNA fragments or oligonucleotide probes fixed on a slide to assess the mRNA abun-
dance in a sample using the complementary binding of single-stranded nucleotide se-
quences. A gene may be represented by one or more probes targeting varying regions
of the gene. Commercially available gene expression microarrays, such as Affymetrix
(www.affymetrix.com) and Agilent Technologies (www.chem.agilent.com) can mea-
sure the full complement of known and estimated genes and gene elements with over
40,000 elements per array. Moving away from fixed array technology, Next Gener-
ation Sequencing Digital Gene Expression is able to measure gene expression at a
much greater dynamic range than available by microarrays [63], and it detects all
32
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transcripts without the need for a priori probe development.
Metabolomics is the high-throughput study of the metabolome, the cellular com-
plement of small molecules. In this work we consider all molecules under 10,000
KDa. This includes such classes as amino acids, fatty acids, simple carbohydrates,
and exogenous drugs within the cell. Metabolomic data are generated by mass spec-
trometry (MS) preceded by either gas or liquid chromatography (GC or LC) [26, 69].
The initial chromatography step separates the molecules so that they can be iden-
tified by their mass spectrum. When this separation step is skipped the metabolic
activity of the cell is measured as a metabolic fingerprint, but metabolites are not
measured individually [18].
Metabolomic studies currently detect between one hundred and one thousand
metabolites [21, 70, 60], compared to the tens of thousands of genes probed on a
microarray [68]. Additionally, unlike a gene expression array, there is no pre-defined
set of metabolites measured in each experimental run. This allows for metabolite
discovery but adds another dimension of missing data in that it is not clear if the
metabolite was not present or simply not detected. Similarly to the estimated se-
quence tags (ESTs) on a gene expression array not all metabolites detected will be
identified [19].
In the classic dogma of biology DNA gives rise to mRNA transcripts as genes are
expressed which direct the construction of proteins. From this view the metabolites
are the functional elements upon which the proteins act. Proteins construct, degrade
or alter metabolites in predictable patterns for energy transfer or other functions
vital to the cell. These reactions can be classified into metabolic pathways and
provide a means for connecting genes to metabolites. Though we know now that
information transfer is not strictly passed from DNA to RNA to proteins this gives
34
us an introductory view of the relationship between mRNA and metabolites.
Integration of gene expression and metabolomic data has been used in the study
of model organisms for gene function discovery as well as sample class differentiation.
Unsupervised classification methods are predominantly used and even recommended
by Weckwerth and Morgenthal (2005) [71] who suggest that supervised analyses may
be particularly biased by choices in data preprocessing. Hirai et al. (2004 [29], 2005
[28]) use principal components analysis and self organizing maps (SOM) to predict
gene function by correlation with metabolite profiles in time series experiments on
Arabidopsis. Unsupervised methods are also commonly used for discrimination of
classes with results of concatenated gene expression and metabolomic datasets often
performing better than either individually [66, 45, 59].
Metabolomic studies in human populations that include gene expression data are
fewer [33, 71]. Most recently, Spicker et al. (2008) [59] looked separately at data
reduction models for genes and metabolites and then jointly from a concatenated
list, finding that the joint model is more interpretable. They discuss the risks of
concatenating such distinct data sets and recommend either block scaling or hier-
archical modelling where the results of the first model (e.g. principal components
analysis) are used to construct a second model. Additionlly, Ferrara et al. (2008) [17]
combined metabolomic and gene expression data with genomic markers to construct
hypotheses regarding causal relationships between genes and metabolites.
Most of the current methods are based on correlation matrices [45, 59, 9]. As
expected, correlation within a platform, such as between metabolites, is higher than
correlations between platforms [17, 9]. Carrari et al. (2006) [9] states that correlation
is low between gene and metabolite and which is supported by Urbanczyk-Wochniak
et al. (2003) [66] who found only 2% of the pairs to have correlation estimates signifi-
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cantly different from zero. However, the magnitude and prevelance of the correlation
varies between studies and may be dependent upon data pre-processing steps chosen.
For instance, Camacho et al. (2004) [8] found that most metabolite-metabolite pairs
had low correlation whereas Ferrara et al. (2008) [17] found a high percentage of
metabolite pairs with correlation over 0.5.
Our motivation is to discover biomarkers in case-control studies. Thus, supervised
methods are of primary interest. We are encouraged by the previously described un-
supervised results that demonstrate better separation of classes when gene expression
and metabolite data are considered jointly. Though, a simple approach to supervised
integration is to analyze the data from each platform independently and then assess
the concordance of the results by looking at unions and intersections of the elements
highlighted in each experiment, we posit that it is more powerful to use a higher
level of data in the integration. We propose that p-value weighting, the method of
adjusting the p-value or threshold of a test according to some a priori importance
measure, is a viable method for the integration of differential analysis. Under the
proper conditions p-values can be weighted without an increase in type I error [20]
and even minimally informative weights can provide power enhancement [54].
In this work we extend the use of p-value weights to a systems biology data
integration. We find that gene expression data can be used to construct weights for
per-metabolite tests providing a boost in power to detect differential metabolites.
We begin with a brief description of the motivating data sets (Section 3.2). In
Section 3.2.2 we discuss p-value weighting and its use in genomics. We follow with a
description of the weighting methods that we consider (Section 3.3). Two simulations
are employed to study these weights in Sections 3.4.1 and 3.4.2. In Section 3.5 we use
the Sreekumar-matched gene expression data to construct weights for the Sreekumar
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et al. (2009)[60] metabolite data. We conclude in Section 3.6 with some discussion
and recommendations.
3.2 Background
3.2.1 Gene expression and metabolic profiling data used
For this work, we use metabolomic data and gene expression data. Metabolomic
data can be derived from mass spectra techniques or other means of high through-
put measurement. Unlike metabolic fingerprinting, which uses the spectral intensities
directly, metabolomics requires an identification step that matches the spectral in-
tensities to distinct compounds, though not all compound will be known. Thus the
data can be represented in an M×NM matrix with M metabolites and NM samples.
Gene expression data is derived from microarrays or other high-througput assess-
ment. The gene expression data can be represented in a G × NG matrix with G
genes and NG samples. For motivation we consider the metabolic profiling data of
Sreekumar et al. (2009 [60]; NM = 28, M = 518) the gene expression data of the
matched samples (GEO number GSE8511, unpublished, NGS = 28, GS > 40, 000),
and the gene expression data of Varambally et al. (2005 [68]; GEO number GSE3325,
NGV = 9, GV > 40, 000).
Each of these motivating examples compares prostate cancer tumor tissues sam-
ples to adjacent benign tissue samples. Tissues are collected from prostate glands
extracted by prostatectomy. Benign adjacent tissue is removed from histopatholog-
ically determined non-tumor sections of the extracted prostate. In the Sreekumar
metabolic data and matched gene expression data, seven men contributed both a
tumor sample and a benign sample. One man contributed three samples; a high
grade tumor sample (Gleason Major: 4, Gleason Minor: 4), a moderate grade tumor
sample (Gleason Major: 4, Gleason Minor: 3), and a benign sample. As not all
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tumor samples have a matched benign sample, we chose to ignore this matching in
our analysis and we treat the samples as independent between case and control.
The metabolomic data set is pre-processed as described in Sreekumar et al. (2009)
[60] and two-sample testing per-metabolite is conducted using Wilcoxon rank-sum
tests with an emprically calculated p-value to assess differences between tumor and
benign tissues [60]. The Varambally dataset was preprocessed using LOESS models
for standardization, as described in Varambally et al. (2005) [68]. The Sreekumar-
matched gene expression was globally standardized by subtracting the median and
dividing by the interquartile range of each sample. The gene expression datasets were
assessed for differential expression using per-gene Welch t-tests. In the following we
consider only the p-value per metabolite, PM = (PM1 , . . . , P
M
M ), and we use either
the test statistic, TG = (TG1 , . . . , T
G
G ), or p-value, P
G = (PG1 , . . . , P
G
G ), per gene.
For integration, the gene expression and metabolomic datasets are mapped to
the pathways defined in the Kyoto Encyclopedia of Genes and Genomes (KEGG
[34, 36, 35]. The mapping between gene and metabolite is not one-to-one, i.e. a
single metabolite may be associated with several genes and likewise a single gene
may be associated with several metabolites (see Appendix A for details). To build
per-metabolite weights, we must summarize the gene information related to each
metabolite. In this chapter we use gene-set enrichment tests to capture the infor-
mation in the gene expression data regarding the differential characteristics of the
genes in a pathway. Specifically, we use either the p-value or test statistic from the
gene set enrichment tests to construct p-value weights for the per-metabolite tests.
3.2.2 Weighted multiple testing and applications to genomic analysis
P-value weighting was suggested by Holm (1979) [30] as a method for control-
ling error while retaining power in multiple testing situations. Consider a set of
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m tests in which a positive constant weight, wi, is applied to each p-value, Pi, for
test i = 1, . . . ,m, according to its perceived importance. Holm then showed that
the sequentially rejective Bonferroni test (now referred to as Holm’s test) could be
generalized to use the new p-value, P ∗i = Pi/wi, to assess significance. Specifically,
if the ordered weighted p-values are written as P ∗(1) ≤ · · · ≤ P ∗(m) then we reject H∗(i)
when





, j = 1, . . . , i
where H∗(i) and w
∗
(i) are the hypothesis and weight associated with weighted p-value
P ∗(i). The weighted Holm’s test (wHT) is designed to control the family-wise error
rate (FWER), i.e. the probability that at least one null hypothesis is falsely rejected,
and does not require that the multiple tests be independent. Holm’s only requirement
for wHT is that wi ≥ 0.
More recently Genovese et al. (2006) [20] proposed p-value weighting with ap-
plication to genomics studies. Instead of Holm’s test, they use the Benjamini-
Hochberg (BHT) step-down test Benjamini and Hochberg (1995) [5] as the basis
of their method. With the BHT, H(1), . . . , H(i) are rejected for maxi=1,...,m{P(i) :
P(i) ≤ iα/m} where H(i) is the hypothesis associated with ordered p-value P(i). The
BHT controls the false discovery rate (FDR), i.e. the expected rate of incorrectly
rejected null hypotheses among all rejected null hypotheses. For testing hundreds,
or thousands, of hypotheses controlling the FDR is less conservative than control-
ling the FWER. Yet, when all null hypotheses are true the FDR and FWER are
equivalent [6].
As with the work of Holm (1979)[30], Genovese et al. (2006) [20] consider the
weight wi ≥ 0 for test i resulting in the weighted p-value, P ∗i = Pi/wi. Again, there
is no requirement on the independence of the tests. However, they allow that the
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set of weights W = {w1, . . . , wm} be random variables and they additionally require
that w̄ = m−1
∑m
i=1wi = 1 to maintain control of the FDR. Then the weighted-
BHT (wBHT) rejects the null hypotheses, H∗(1), . . . , H
∗
(i) for maxi=1,...,m{P ∗(i) : P ∗(i) ≤
iα/m}, where H∗(i) is the hypothesis associated with ordered weighted p-value P ∗(i),
while controlling the FDR at level α.
With only two requirements on the weights, Genovese et al. (2006) [20] note
that p-value weighting is quite flexible. In fact they show that for binary weighting
schemes, where all hypotheses are either up-weighted by w1 or down-weighted by w0,
the power is improved for informative weight choices and is only minimally reduced
for completely non-informative weights [53]. The concern for power loss stems from
the required balancing of the weights across all tests such that, w̄ = m−1
∑m
i=1wi = 1.
Here all up-weighting must be balanced by equal down-weighting. If the up-weighting
is sparse, the weight can be strong as the down-weight is spread over many tests. In
contrast, broadly applied up-weights must be more moderate to reduce the effect of
the down-weights. More recently, Roeder et al. (2009) [55] showed this to be true and
found that the power can be greatly increased when sparse weights are well assigned,
yet, they also show that the power loss is small for poorly assigned weights. For
broad coverage of up-weighting they show that there is only small power loss for
poorly specified weights and that in most cases the weighted tests have more power
than the un-weighted tests.
Roeder et al. (2006) [53] applied the wBHT to large-scale genomic studies where
thousands of tests are performed and controlling the error rates leads to a loss of
power. Multiple testing adjustments are particularly problematic for the identifica-
tion of subtle changes that are of most interest. In their work, Roeder used linkage
studies to construct p-value weights to improve the power to identify disease variants
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in genome wide association studies (GWAS).
Consider the linkage test statistic zi at locus i where Zi ∼ N(µ, 1) with µ = 0
for unlinked loci and µ > 0 for linked loci. Here the information from the linkage
test is contained in the parameter µ. They define two functional relations between
µ and the test statistic zi to use for weight construction. First they consider the
posterior odds that a locus is linked which is proportional to vi = exp(ziµ). They
also consider the standard normal cumulative distribution function (CDF), Φ(·) ,
such that vi = Φ(zi − µ). In both cases the values vi must be standardized to form
weights wi = vi/v̄ that meet the requirement that w̄ = m
−1 ∑m
i=1wi = 1. The
strength of the weights is determined by the choice of µ̃ to estimate µ.
By simulation, Roeder et al. (2006) [53] found that both continuous weighting
schemes were near to one when no linkage signal was simulated. With stronger
linkage signals the weights increased. The posterior odds weights increased more
dramatically and had high variance resulting in spikes in the informative regions.
The CDF weights showed less intensity and lower variance. They had broader peaks
but that resulted in deeper down weights due to the average weight constraint. For
highly informative data the posterior odds weighting is ideal since they provide sparse
weights. The cumulative weights are preferred when there is less certainty in the prior
data, however, the up-weighting must be moderate to avoid strong down-weighting.
There are no restrictions on the weighting functions and others may be used [51].
However, the choice of weighting function should have a meaninful interpretation and
Roeder et al. (2006) [53] wisely advise that they should be chosen prior to analysis
of the data to be weighted.
In the context of metabolomic profiling we have hundreds of tests, not thousands,
and we are concerned with improving the power of the per-metabolite tests regardless
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of multiple test correction. Low sample numbers and high inter- and intra-person
variation due to diurnal rhythm, diet, and other environmental factors contribute to
low power to detect differential metabolites. Yet, metabolites do not act in isolation
within the cell. Here we use p-value weights to add information about the behavior
of other molecular components such as gene transcripts in an effort to add power to
nominate metabolites of interest. Through simulations described in Sections 3.4.1
and 3.4.2 we find that the power can be improved without raising the Type I error
rates relative to the unweighted tests.
3.3 Proposed weight functions
Let us denote the metabolomic data by ylm, for samples l = 1, . . . , NM and
metabolites m = 1, . . . ,M . Likewise denote the gene expression data by xjg for
samples j = 1, . . . , NG and genes g = 1, . . . , G. We integrate these two datasets
using the KEGG pathway maps k = 1, . . . , K. As the genes and metabolites do not
have a one-to-one mapping we must summarize the information in the gene expres-
sion data to construct the weights. Here we use enrichment testing to capture the
information about the differential gene expression data per pathway. That is, each
gene is assessed for its ability to differentiate diagnostic classes, say by a two-sample
t-test, as captured by the statistic TGg , g = 1, . . . , G. An enrichment test assesses
the level of differential ability within a pathway k.
As listed in Table 3.1 we consider four different enrichment test types. First we
consider tests based on either binary or continuous differential expression results.
Binary tests require that the per-gene tests are thresholded to categorize each gene
as “differential” (e.g. |TGg | ≥ τ) or “non-differential” (e.g. TGg < τ), for a given
threshold τ . Continuous tests use the per-gene test statistic, TGg , in its continuous
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form. The benefit of the continuous tests is that does not rely on an arbitrarily
defined threshold.
Second, we consider the null hypothesis style of the test, namely competitive ver-
sus self-contained [24]. A competitive test compares the genes in the set of interest,
say set ξ, to all other genes, say set ξc. The null hypothesis is that ξ contains the
same proportion of differential genes, say π, as ξc. A self-contained test considers
only the genes within the set of interest, ξ, and ignores the genes in ξc. The hypoth-
esis is that there are no more differential genes than expected where the expected
value is determined a priori, i.e. 5% based on an α = 0.05 error rate, or by sample
permutation. Competitive tests allow selection of a “best” set, that is one that is
enriched above the rest, but they are limited such that a given set ξ′ with π percent
differential genes will receive a different test statistic depending upon the proportion
of differential genes, say πc, in the set (ξ′)c. Self-contained tests will always give the
same result for the same set of data since the test of ξ does not depend on ξc. How-
ever, if differential genes are uniformly distributed across all pathways, that is πk = π
for all k = 1, . . . , K, then all pathways will be called enriched by a self-contained
test if π is great enough.
Each of the four enrichment tests listed in Table 3.1 will be described in Section
3.3.1. The enrichment tests capture the gene expression information in each pathway
k, k = 1, . . . , K, by a test statistic Sk or its corresponding p-value P
E
k . To utilize this
information as a weight we first transform it using one of five weighting functions
described in Section 3.3.2.
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Table 3.1: Four gene-set enrichment tests are considered. The competitive hypergeometric
and weighted Kolmogorov-Smirnov tests compare the level of differentiation in the set of
interest to all other sets. The self-contained binomial and sum of squared statistics tests
are global tests of differentiation within the set. Thresholding of per-gene tests prior to
enrichment testing is required for the hypergeometric and binomial tests.
Competitive Self-contained
Binary Hypergeometric Binomial
Continuous Weighted Kolmogorov-Smirnov Sum of Squared Statistics
3.3.1 Enrichment test methods
Directional Hypergeometric Test
For a given pathway ξk, each gene tested (T
G
g , g = 1, . . . , G) is categorized by
its inclusion in the pathway (g ∈ ξk) and whether it is differentially expressed (e.g.
|TGg | ≥ τ , for a given τ). This categorization is depicted in Table 3.2. In the fol-
lowing we use two-sample t-tests for assessing per-gene differential expression. We
then threshold the test statistics at |TGg | ≥ τα where τα is chosen according to a t-
distribution with NG−2 degrees of freedom and α = 0.05. We use a directional test of
enrichment, Pr(X ≥ x|Gk = gk, G0 = g0, D = d), assuming X ∼ Hyper(Gk, G0, D),
where X, Gk and G0 are defined as in Table 3.2. Assuming a hypergeometric distri-
bution for this 2x2 table, we can get an exact p-value without permutation testing
and we use Sk = Xk as the statistic of interest. Because the hypergeometric test uses
the genes of ξck to define the null proportion of differential genes, this is a competitive
test. This test differs from the Fisher’s Exact test in that it does not consider the
depletion of differential genes in a pathway ξk as an interesting case.
Table 3.2: The classification of genes that underlies the gene set enrichment testing.
Competitive tests consider the entire table whereas self-contained tests focus on the first
row.
Differential Not Differential Total
In Pathway ξk X Gk −X Gk
In Pathway Complement ξck D −X G0 − (D −X) G0
Total D G−D G
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Binomial Test of Proportions
Also called Tukey’s Higher Criticism [24], the binomial test of proportions is self-
contained such that only genes contained in pathway ξk are considered for the test of
that pathway (i.e. the top row of Table 3.2). Specifically we test the null hypothesis
that X ∼ Bin(Gk, α) and we reject if X/Gk ≥ x where α is set a priori and X
and Gk are defined as in Table 3.2. In the following we set α = 0.05 as this is the
assumed error rate for each of the per-gene differential tests, TG = (TG1 , . . . , T
G
G ).
Significance is determined using permutation sampling of the NG sample labels to
construct the null distribution or, in the simulation, draws from the null distribution
of test statistics. The test statistic of interest is Sk = Xk/Gk for each pathway k.
Weighted Kolmogorov-Smirnov Test
A weighted Kolmogorov-Smirnov (K-S) test is used to compare the test statistics
of those genes in the pathway k, i.e. TGg : g ∈ ξk, against the statistics of those not in
the pathway and thus is a competitive test. The K-S test compares the two groups of
test statistics in a single ranked list, testing if they arise from the same distribution
by assessing the spread of the two sets throughout the ranked list. Specifically,
begin by ranking the vector of t-statistics TG as (TG(1), T
G
(2), . . . , T
G
(G)). Construct
a corresponding pathway inclusion indicator vector γ = (γ(1), γ(2), . . . , γ(G)) where
γ(g) = 1 if g ∈ ξk and 0 otherwise. The statistic Sk is then maximum deviation of
the empirical distributions
(3.2) Sk = maxh|P (ξk, h)− P (ξck, h)|
where











Here νg ∈ [0, 1] is the weight for gene g and an unweighted K-S test would have
νg = 1 for all g = 1, . . . , G. Additionally, Gk is the number of genes in ξk; see Table
3.2.
The weighted K-S test as proposed by Subramanian et al. (2005) [61] uses νg =
|corrj(xjg, ψj)|. That is, each gene g is weighted by the correlation across samples, j
between the expression value xjg and the case status ψj, where ψj = 1 for cases and
0 for controls. In this way tests that cluster in the tails of the ranked list are given
higher weight. In our simulations we define νk based on a function of the simulated
test statistic νg = |Zg|/(1 + |Zg|). We choose a Z-score based weight for conveience
in our simulation but the relationship between the Pearson’s correlation coefficient
in the Subramanian νk and Z score is monotonic so only the magnitude of the test
statistic will be affected. Significance is determined using permutation sampling of
the sample sample labels ψj to construct the null distribution or, in the simulation,
draws from the null distribution of test statistics.
Sum of Squared Test Statistics
The test statistic from the the sum of squared test statistics method is simply the





Significance is determined using permutation sampling of the NG sample labels to
construct the null distribution or, in the simulation, draws from the null distribution
of test statistics. This is a self-contained test since Sk and its null distribtution
consider only the genes in ξk.
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3.3.2 Weight functions
The above enrichment tests provide a test statistic, Sk, and corresponding p-value,
PEk , that summarize the level of differential expression in each pathway k = 1, . . . , Nk.
To utilize these data as p-value weights we must transform them to ensure that they
are positive and that they increase with increasing levels of differential expression,
that is they must be positively correlated with increasing importance. We may also
want to adjust the scale or distribution of the enrichment information for better
performance under the w̄ = m−1
∑m
i=1wi = 1 restriction.
We consider five functions of the enrichment test information, ωk. These are (A)
ωk = − log10(PEk ), (B) ωk = |Sk|, (C) ωk = |S̃k|, (D) ωk = Φ(S̃k − µ̃), and (E)
ωk = exp(S̃kµ̃) where Sk is the test statistic and P
E
k is the p-value from the enrich-
ment test of gene expression values for pathway k. S̃k = (Sk−E(S0))/
√
V ar(S0) is a
standardized test statistic using the null distribution of the test statistic to determine
the mean, E(S0), and variance, V ar(S0), of S0. Here Φ(·) is the cumulative distribu-
tion function (CDF) for the standard normal distribution. We set the parameter µ̃
to 2 according to Genovese et al. (2006) [20]. Higher µ̃ results in more conservative
weights for the CDF function (D) by shifting the distribution of Sk. Higher µ̃ results
in stronger weights for the exponential function (E).
We chose to explore the weight functions suggested by Roeder et al. (2006) [53],
termed weights D and E here, as they present both bounded (D) and unbounded (E)
options for weight construction. We expect that the bounded weights of the CDF
function (D) will out-perform the strong peaks of the exponential function (E) in
this application to metabolomic data. Specifically, applying the same weight to all
members of a pathway is contrary to the sparse nature of the exponential function
weighting and strong downweighting is likely to arise. We also considered some more
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simplistic functions based directly on the enrichment p-value and statistic (weights
A, B, and C).
To apply these pathway level weight to the per-metabolite p-values, PMm = 1, . . . ,
PMM , we first associate the component ωk with each metabolite in the pathway, say
vi = ωk for metabolite i in pathway ξk. The weights must then be standardized
such that wi = vi/v̄ where v̄ =
∑m
i=1 vi to arrive at wi. Finally, we define P
M∗
i =
PMi /wi and P
M∗
i can be assessed for significance in the usual way. As many of the
metabolites in the KEGG pathways are associated with more than one pathway,
additional summarization of the pathway weights ωk must be done such that vi =
f(ωkI(i ∈ k)) where I(i ∈ ξk) is an indicator function for metabolite i in pathway k
and f(·) is a summary function. In Section 3.4.2 we explore median and seventy-fifth
percentile summaries.
3.4 Numerical examples
The simulations were programmed using the R statistical software v 2.7 and
greater. SAS v. 9.1 was used for preparation of the real datasets. The gene
and metabolite information for each human pathway map in KEGG was acquired
from KEGG version 50 (April 2009) using perl scripts and the KEGG API [37].
The Varambally et al. (2005) [68] gene expression measures are from an Affymetrix
HU133Av2 genechip and the gene symbols were obtained from GEO (Gene Ex-
pression Omnibus, www.ncbi.nlm.nih.gov/geo, GSE3325, August 2009) using the
GPL570 platform information file. The Sreekumar-matched gene expression mea-
sures are from an Agilent Whole Human Genome Oligo Array (data: GSE8511 (pri-
vate), platform: GPL1708, March 2008). We use these gene expression data sets in
combination with the Sreekumar et al. (2009) [60] metabolomic data to construct two
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simulation situations. We begin with a simplistic model with disjoint pathways such
that every metabolite contributes to only one pathway. Following is a more complex
dataset with pathways modelled from the KEGG pathway mapping of the real data.
The simplistic model allows us to explore properties of the different weight func-
tions in an easily interpretable setting. The complex model provides a more realistic
scenario with which to test our methods where the truth is still known.
3.4.1 Simulation I: Disjoint Pathways
Simulation Model I
Z-scores are simulated from a standard multivariate normal distribution to rep-
resent the per-gene test statistics of differential expression and per-metabolite test
statistics of differential intensity. A constant correlation between like elements, i.e.
gene-gene (ρGG) and metabolite-metabolite (ρMM), and a constant but lesser cor-
relation between gene and metabolite (ρGM) within a pathway are assumed. For
simplicity we assume that pathways are disjoint, that is no element appears in mul-
tiple pathways and there is no correlation between elements in different pathways.
The case of non-disjoint pathways will be considered in Simulation II.
We model each pathway to have NGk genes and N
M
k metabolites. We draw a vector
of z-scores (ZG, ZM), where ZG = (zG1 , . . . , z
G
NGk




(ZG, ZM) ∼MVN((β, φ),Σ).
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The variance covariance matrix is defined per pathway as
Σ =
















where ρGM < min(ρGG, ρMM). Under the null model (β, φ) is a vector of zeros.
Under the alternative model, z-scores are simulated from a multivarite normal
distribution with the same variance-covariance matrix, (Σ), of the null model but
with shifted means (β1 = · · · = βNGk = β > 0 and φ1 = . . . = φNMk = φ > 0). Genes
and metabolites are drawn from this alternative model according to a Bernoulli(π·k)
distribution thereby assigning some elements to be truly differential. The probability
of differential elements can differ for genes, πGk ∈ [0, 1], and metabolites, πMk ∈
[0, 1]. We also allow πGk and π
M
k to differ by pathway (k) thereby defining some
pathways to be enriched. We retain the simulated state of differential intensity for
each metabolite, i ∈ (i, . . . ,M) in the vector H where Hi = 0 for the null case and
Hi = 1 for the differential case. P-values are calculated from the simulated z-scores
using the standard normal distribution, i.e. p = 2Pr(|Z| ≥ zα/2).
We consider a scenario with 50 pathways and allow the following parameters to
vary:
• Alternative means (β, φ): (1.5, 2), (1.5, 3), (2,3)
• Pathway size (NMk , NGk ): (3, 20), (5, 40)
• Percentage of enriched pathways: 10%, 20%
• Correlation between like elements (ρMM , ρGG): 0.2, 0.4, 0.6
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• Correlation between gene and metabolite (ρGM): 0.0, 0.10, 0.15, 0.25, 0.50 where
ρGM < min(ρGG, ρMM)
To attain the desired level of enrichment, we set (πMk , π
G
k ) = (0.75, 0.50) for enriched
pathways and (πMk , π
G




k ) = (3, 20).
For the larger pathways, (NMk , N
G




k ) = (0.50, 0.25) for
enriched pathways and (πMk , π
G
k ) = (0, 0) otherwise.
Each of the four enrichment tests described in Section 3.3.1 was applied to the
gene expression z-scores for each of the 50 pathways. For tests requiring it, the
null distribution was simulated by the generation of 1000 null vectors of z-scores
(πGk = π
M
k = 0.05 for all k). The enrichment test statistic (Sk) and p-value (P
E
k )
for each pathway (k = 1, . . . , 50) was retained. Each of the five weight functions of
Section 3.3.2 was then applied: (A) ωk = − log10(PEk ), (B) ωk = |Sk|, (C) ωk = |S̃k|,
(D) ωk = Φ(S̃k − µ̃), and (E) ωk = exp(S̃kµ̃). The standardized test statistic,
S̃k = (Sk − E(S0))/
√
V ar(S0), uses the 1000 null vectors to determine the null
mean, E(S0), and null standard deviation, V ar(S0). Estimates of the mean and
variance were determined from the hypergeometric distribution for the directional
hypergeometric test. Again, Φ(·) is the cumulative distribution function (CDF) for
the standard normal distribution and we set µ̃ = 2 unless otherwise noted.
With four enrichment scores and five weight functions we have twenty weights
constructed for each pathway, ωkj where j = 1, . . . , 20. The pathway level weights
can be applied to the simulated metabolite p-values for each pathway such that
vij = ωkj for metabolite i in pathway k and weight option j. The weights are then
standardized, wij = vij/v̄·j where v̄·j =
∑m
i=1 vij. The per-metabolite p-values are
determined from the z-score vector ZM by comparing the z-scores to a standard
normal distribution, i.e. PMi = 2Pr(|ZMi | ≥ zα/2). The weighted per-metabolite p-
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i /wij. This results twenty weighted p-values
for each metabolite, i.e. an NM × 20 matrix.
To assess the Type I error rate for each method, with respect to metabolites,
we simulated the situation of completely null data by generating Z-scores under a
model where πGk = π
M
k = 0 for all k. We also simulated a second null setting in
which we assume that there are differentially expressed elements but that they are
not associated with the pathways. Here we set πGk > 0 and π
M
k > 0 to be constant
non-zero rates for all pathways, k ∈ (1, . . . , K), to generate differential elements
uniformly across all pathways. The second null model helps us to determine error
rates and to assess any power loss from the marginal weighting of the null pathways.
The power, or the probability of correctly identifying a differential result, is assessed
using the true state of metabolite differential intensity, Hi, as simulated by the
Bernoulli(πMk ) draws. We use receiver operating characteristic (ROC) curves, varying
the significance threshold for PM∗i , and the associated area under the curve (AUC)
to compare the properties of the different methods.
Results for Simulation Model I
Graphical representation of the results are presented in a 2 × 2 grid mimicking
Table 3.1 with each enrichment test occupying a quadrant of the figure. Each of the
five weight functions is labelled A–E and color coded . This coloring is consistent
throughout the paper where the unweighted (raw) p-values are black, and the five
weight functions are (A), ωk = −log10(p), green; (B), ωk = |S|, blue; (C), ωk = |S̃|,
purple; (D), ωk = Φ(S̃ − µ̃), orange; and (E), ωk = exp(S̃µ̃), red. Average ROC
curves, across the simulation runs, are used to compare the sensitivity and specificity
of correctly identifying differential metabolites. Boxplots are used to demonstrate
differences in error rates under the null models.
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The null model in which no genes and no metabolites are selected to be differential
(πGk = π
M
k = 0 for all k) was simulated for varying correlations. Figure 3.1 shows
a representative plot of the error rates for 1000 replications of the simulation where
NGk = 20, N
M
k = 3, ρGG = ρMM = 0.20 and the correlation ρGM ∈ (0, 0.1, 0.15).
We see that the Type I error is near the nominal level when there is no correlation
between genes and metabolites. In some cases the error rate may increase slightly as
the correlation increases. However, the boxplots each overlap the nominal 0.05 error
rate (black horizontal line) except for the exponential weight function (E, red) which
is conservative. Additionally, we are simulating uniform correlation within pathways.
In reality we find from assessment of the Sreekumar metabolite and Sreekumar-
matched gene expression data that pairwise correlation of genes and metabolites
across matched samples are highly correlated for only about 8% of the pairs by
pathway. This result is supported by Urbanczyk-Wochniak et al. (2003) [66] who
find only 2% of the total pairs to be significantly correlated. Thus this Type I error
estimate is likely conservative and actual error may be lower.
Under the second null model we assume that there are differential metabolites
and genes in the dataset but that they are uniformly distributed across the dataset,
that is simulated without pathway enrichment. Figure 3.2 shows the Type I error
rates for 1000 replicates of the simulation with πGk = π
M
k = 0.1 for all k, N
G
k = 20,
NMk = 3, ρGG = ρMM = 0.20 and the correlation ρGM ∈ (0, 0.1, 0.15). Figure 3.3
shows the Type I error for the same settings except that ρGG = ρMM = 0.60 and the
correlation is explored up to ρGM = 0.50. We see more Type I inflation in these high
correlation cases. We do not expect such high correlations to exist in our data but
high correlations have been observed by others [9].
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0 10 15 0 10 15 0 10 15 0 10 15 0 10 15 0 10 15Correlation
Sum of Squared Statistic
Figure 3.1: Type 1 error for per-metabolite tests using a significance threshold of α = 0.05 without
multiple testing adjustments. 1000 datasets were simulated assuming within pathway
correlation of 0.2 for each metabolites and genes. Unweighted (Raw) p-values and the
five weight functions (A, −log10(p); B, |S|; C, |S̃|; D, Φ(S̃−µ̃); E, exp(S̃µ̃)) are depicted





























































Raw A B C D E


































































Raw A B C D E


























































Raw A B C D E





































































Raw A B C D E
0 10 15 0 10 15 0 10 15 0 10 15 0 10 15 0 10 15Correlation
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Figure 3.2: Type 1 error, under uniformly distributed differential elements, for per-
metabolite tests using a significance threshold of α = 0.05 without multiple testing
adjustments. 1000 datasets were simulated assuming within pathway correlation of 0.2
for each metabolites and genes and πGk = π
M
k = 0.1 for all k. Unweighted (Raw) p-
values and the five weight functions (A, −log10(p); B, |S|; C, |S̃|; D, Φ(S̃− µ̃); E, e(S̃µ̃))
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Sum of Squared Statistic
Figure 3.3: Type 1 error, under uniformly distributed differential elements, for per-
metabolite tests using a significance threshold of α = 0.05 without multiple testing
adjustments. 1000 datasets were simulated assuming within pathway correlation of 0.6
for each metabolites and genes and πGk = π
M
k = 0.1 for all k. Unweighted (Raw) p-
values and the five weight functions (A, −log10(p); B, |S|; C, |S̃|; D, Φ(S̃− µ̃); E, e(S̃µ̃))
are depicted with increasing between element correlation, ρGM ∈ (0, 0.1, 0.15, 0.25, 0.5).
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i.e. the gene expression data is not informative by pathway. On average the loss is
between 5–15 points on the AUC scale, except for the exponential weight function
where the conservative error rates seen above are reflected in the poor power. Figure
3.4 shows the ROC curves and AUC levels for each method under this null model with
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Mean 86 76 82 73 76 62
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AUC Raw A B C D E
Mean 86 82 74 80 76 56
(SEM) (0.64) (0.75) (0.8) (0.77) (0.81) (0.69)
Figure 3.4: Power loss under uniformly distributed differential elements is depicted by
the average ROC curve for 1000 simulated datasets with πGk = π
M
k = 0.1 for all k,
ρGG = ρMM = 0.2, and ρGM = 0.1.
When there is enrichment in a subset of the pathways three of the five weight
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functions show robust increases in power over the unweighted case (raw, black);
the p-value weight (A, green), the standardized test statistic (C, purple), and the
CDF transformation (D, orange). Figure 3.5 shows the average receiver operating
characteristic (ROC) curves from 100 simulated datasets where the alternative means
are (β, φ) = (2, 3). This representative plot is of data with pathway sizes (NMk , N
G
k ) =
(3, 20) and correlations ρGG = ρMM = 0.2 and ρGM = 0.10. Ten of 50 pathways (20%)
are simulated to be enriched with at (πMk , π
G
k ) = (0.75, 0.50) for k ∈ (1, . . . , 10) and
(πMk , π
G
k ) = (0, 0) otherwise. Increasing the correlation to ρGG = ρMM = 0.6 and
ρGM = 0.15 provides only a marginal increase in the AUC for the absolute statistic
(B, blue) and exponential (E, red) weight functions, see Figure 3.6. The other weight
functions appear to have a minimal loss of power, e.g. AUC=98 versus AUC=96 for
the hypergeometric test p-value weight (A, green) in this higher correlation model.
When we reduce the effect size of the differential elements to have alternative
means (β, φ) = (1.5, 2) there is still a substantial increase in power for the p-value
weight (A, green), the standardized test statistic (C, purple), and the CDF transfor-
mation (D, orange) with AUC values of 90 or greater (see Figure 3.7).
As expected from the recommendations of Roeder et al. (2006) [53], the exponen-
tial weight function (Figure 3.5 – 3.7, E, red) is poorly suited for this application.
The exponential function, ωk = e
(S̃µ̃), provides strong weights and is best suited for
defining sparse up-weights. The balancing down-weights are then spread across the
remaining tests. In the simulations presented thus far we have looked at situations in
which 20% of the pathways are enriched leading to approximately 20% up-weighting.
Given the small number of metabolites tested, compared to genomic studies, the cor-
responding down-weighting is only shared across a couple hundred metabolites. The
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AUC Raw A B C D E
Mean 86 97 22 98 98 61
(SEM) (0.49) (0.15) (0.59) (0.12) (0.12) (0.73)
Figure 3.5: Average receiver operating characteristic (ROC) curves (n=100) depict the
sensitivity and specificity for each test method and weight function when applied to
per-metabolite tests. Data are simulated assuming within pathway correlation of 0.2
for each metabolites and genes and between element correlation of 0.1. Ten of fifty
pathways were simulated as enriched where differential test statistics have mean of two
and three for metabolites and genes, respectively. The mean area under the curve
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AUC Raw A B C D E
Mean 85 95 35 95 97 65
(SEM) (0.62) (0.24) (0.86) (0.31) (0.24) (0.94)
Figure 3.6: Average receiver operating characteristic (ROC) curves (n=100) depict the
sensitivity and specificity for each test method and weight function when applied to
per-metabolite tests. Data are simulated assuming within pathway correlation of 0.6
for each metabolites and genes and between element correlation of 0.15. Ten of fifty
pathways were simulated as enriched where differential test statistics have mean of two
and three for metabolites and genes, respectively. The mean area under the curve
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AUC Raw A B C D E
Mean 76 93 24 92 94 65
(SEM) (0.64) (0.33) (0.75) (0.4) (0.35) (0.87)
Figure 3.7: Average receiver operating characteristic (ROC) curves (n=100) under the
same simulation conditions as in Figure 3.5 except that differential test statistics have
mean of 1.5 and 2 for metabolites and genes, respectively.
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set µ̃ = 2 thus far. When we consider reducing the parameter to µ̃ = 1 we see that
the exponential weight method (E, red) is improved but not to the level of the CDF
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Mean 86 96 72 98 61
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AUC Raw D.1 E.1 D.2 E.2
Mean 85 96 79 97 65
(SEM) (0.62) (0.22) (1.1) (0.24) (0.94)
Figure 3.8: Average receiver operator characteristic (ROC) curves (n=100) assuming
µ̃ = 1. The CDF transformation (D, orange) and exponential (E, red) weight functions
are shown for the sum of squared statistic enrichment test. For comparison, both µ̃ = 1
(solid lines) and µ̃ = 2 (dotted lines) are plotted (i) under low correlation conditions as
in Figure 3.5 and (ii) under high correlation conditions as in Figure 3.6.
The absolute value of the test statistic (Figure 3.5, B, blue) has poor AUC in most
scenarios. We expect that this is primarily because the unstandardized enrichment
test statistics vary so dramatically that the standardized weights must be very ex-
treme in order to sum to one. It is interesting to note that the absolute statistic (B,
blue) has appropriate error control (see Figures 3.1 and 3.2) and minimal power loss
(see Figure 3.4) in the null cases. Perhaps under the null the variability of the path-
way enrichment scores is low since no pathways are modelled as enriched resulting
in more stable weight values.
In contrast, the p-value weight (A, green), the standardized test statistic (C, pur-
ple), and the cdf of the test statistic (D, orange) are all consistently more powerful
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than the unweighted p-value (Figures 3.5 – 3.7). We consider the potential weak-
nesses of each in turn. First, like the exponential or absolute test statistic weights,
the p-value weight can become quite large when tests of pathway enrichment are
significant. Having one strongly enriched pathway could produce down-weighting in
the other pathways resulting in power loss. However, notice that for three of the
four set enrichment tests the p-value is determined by permutation test. Here we use
1000 permutations so the precision of the p-value cannot be lower than 1/1000 and
thus the negative log10 value will not be greater than 3. The hypergeometric test
is an exact test and the p-value precision is thus limited by the sample size. These
constraints put a ceiling on the range of the negative log10 p-values under which
restriction they appear to behave well.
The absolute standardized statistic (C, purple) and the CDF function (D, orange)
behave similarly. The standardized statistic reduces the magnitude of the statistic
and reigns in the extreme values that occur prior to standardization. The CDF
weight function is based on the standard normal density and thus it works well with
the standardized test statistic. The benefit to using the CDF function is that it
smooths out the test statistic thus reducing the effect of extreme test statistics. We
ran a set of simulations using a multivariate t-distribution for drawing test statistics
under the alternative hypothesis. The heavy tails of the t-distribution resulted in
reduced power with the standardized statistic weight (C, purple) but not the CDF
weight (D, orange) in the non-thresholded tests (see Figure 3.9). However, the power
was still above that of the unweighted test and continued to show comparable power
gains for both weight functions.and continued to show comparable power gains for
both weight functions. The thresholded tests were not affected as they do not use













Sum of Squared Statistic







AUC Raw.T C.T D.T Raw C D
Mean 87 94 98 86 98 98
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AUC Raw.T C.T D.T Raw C D
Mean 88 91 97 85 95 97
(SEM) (0.62) (0.8) (0.25) (0.62) (0.31) (0.24)
Figure 3.9: Average receiver operator characteristic (ROC) curves (n=100) under a
multivariate t-distribution alternative. The standardized statistic (C, purple)
and the CDF transformation (D, orange) weight functions are shown for the sum of
squared statistic enrichment function. Results from per-gene test statistic simulation
models using both the t-distribution (solid lines) and the Normal distribution (dotted
lines) alternatives are plotted (i) under low correlation conditions as in Figure 3.5 and
(ii) under high correlation conditions as in Figure 3.6.
3.4.2 Simulation II: KEGG Based Pathways
Simulation Model II
This simulation makes use of the data structure of the KEGG pathways between
genes and metabolites to define the pathways. This introduces overlapping pathways
and pathways of varying sizes into the simulation. Rather than drawing the data
from a multivariate normal distribution we use bootstrap resampling of published
gene expression data to populate our vector of per-gene test statistics. The metabo-
lite data is modeled from Sreekumar et al. (2009) [60]. Here we have 12 prostate
cancer tissues from localized tumors of varying grade and 16 benign prostate tissues
taken from resected prostate tissues. The gene expression experiment was performed
by the same group (GEO:GSE3325 [68]) so we expect that the tissue diagnosis is
consistent between the two experiments. There are five localized prostate tumor
64
Table 3.3: Fifteen metabolites were chosen to be differential. These metabolites are associ-
ated with up to five pathways, of which up to two pathways are simulated as enriched.
Metabolite 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Number of Pathways 5 5 5 4 4 3 3 3 2 2 2 1 1 1 1
Number Enriched 2 1 0 2 0 2 1 0 2 1 0 1 1 0 0
samples and four benign prostate samples in the gene expression study. Further
sample information and mapping details can be found in Appendix A.
For the simulation we selected eight of 76 pathways that have between 10 and 100
genes measured to be enriched. We then selected 15 (10.2%) of the metabolites to be
differential. These metabolites were selected in such a way that they are members
of between one and five pathways with up to two of the pathways being enriched
(see Table 3.3). By examining metabolites in multiple pathways we can assess the
affect of weight summaries across pathways. By examining metabolites that are not
in enriched pathways we can examine potential power loss due to down-weighting.
The Varambally gene expression data were analyzed per gene using a two-sample
t-test with pooled variance. All 126 permutations of the samples were run and the t-
test recalculated to form the permutation null distribution. To prevent overcounting,
the t-statistics were averaged across probes by gene symbol prior to gene set enrich-
ment testing. All four enrichment tests, as described for Simulation I (Section 3.4.1)
were run on the gene expression data. Additionally, all five weight functions were cal-
culated (Section 3.3.2). To accomodate metabolites that belong to multiple pathways
we summarized the ωk values across pathways within metabolite, vij = f(ωjkI(i∈k)).
The weights were then standardized to average to one, wij = vij/v̄·j. We consider
both the median and the 75th percentile as the summary statistics, f(·).
The per-gene test statistic data are simulated by randomly sampling the 2375
mapped genes, with replacement, from the t-statistic matrix (t-statistic and 126
65
permutation statistics). To induce enrichment, the genes in the enriched pathways
were randomly selected according to a Bernoulli(π) distribution from the subset of
genes that were differential (n=177 at α = 0.05), where π ∈ (0.2, 0.5). That is on
average 100π% of the genes in an enriched pathway were selected to be differential
with an effect size seen in the Varambally data.
The 147 metabolite p-values were drawn from a uniform distribution on [0,1].
Those 15 metabolites that were selected to be differential are chosen from a Beta(3,
37) distribution. The shape parameters were chosen for a mean of 0.075 and a
relatively narrow variance to provide the marginal p-values of interest. Specifically,
the probability of selecting a p-value less than 0.05 is approximately 31% whereas
the probability of selecting a p-value greater than 0.2 is less than 1%. The gene-
set enrichment tests, weight functions, and per-metabolite weights are calculated for
each of 1000 generated gene expression datasets and metabolite p-value vectors.
Results for Simulation Model II
Figure 3.10 shows the frequency of significant p-values (at α = 0.05) for each of the
15 differential metabolites across the 1000 simulated data sets under π = 0.2. The
color scheme and quadrant style figure is retained from the first simulation (Section
3.4.1). Additionally we denote the median summary weights by circles and the 75th
percentile weights by triangles. Notice that these weights are similar but not exact
for the four metabolites in a single pathway. Even though their vij measures will be
identical they are standardized against v̄·j which will vary depending on the other
vi′j values (i
′ 6= i). The black squares represent the unweighted test p-value and, as
expected by the Beta(3,37) distribution used in simulation, they are significant in
about 30% of the datasets.
We quickly see in Figure 3.10 that there are a few metabolites that are weighted
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well by the pathway data and show great power increases; namely metabolite 5(2)
and the first 1(1) metabolite. Additionally, the CDF method (D, orange) appears
to increase success of identifying these metabolites in most situations. It does show
power loss for those metabolites that have no associated gene expression pathway en-
richment such as 3(0). As expected, the exponential weights (E, red) perform poorly
in most cases; performing well for only the two strongest metabolites and severely
downweighting the others. However the unstandardized absolute test statistic (B,
blue) does better than expected in some situations such as with the hypergeometric
test.
The 132 metabolites that were not chosen to be differential can be used to de-
termine false positive rates by considering the percentage of significant calls per
metabolite across the 1000 simulated data sets. In Figure 3.11 these percentages are
plotted as boxplots per weight function. The nominal 5% error rate is noted with a
black horizontal line. For most weight methods the majority of the metabolites have
error near the nominal line, i.e. the box contains 5%. The unweighted tests (black)
are tightly centered at 0.05 as expected by the simulation design. There are some
methods, however, that have high error rates for a handful of metabolites. Specif-
ically, the exponential function (red) behaves poorly with all four enrichment tests
with error rates reaching 50% for some metabolites. The p-value weighting method
(green) has higher error for the hypergeometric test and the Kolmogorov-Smirnov
test. Surprisingly, the absolute test statistic (blue) has low error in all cases except
for the binomial test. The CDF function (orange) has low error in the self-contained
tests (binomial and sum of squared statistic). There is no obvious difference between
the median summary and the 75th percentile summary with respect to the error
rates (see Figure 3.11). The 75th percentile may has a slight advantage in the rate
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Figure 3.10: The frequency of a significant call for each of the fifteen differential metabo-
lites. The metabolites are noted on the vertical axis by the number of associated path-
ways (enriched) for that metabolite. The weight functions are color coded as before
(A, green; B, blue; C, purple; D, orange; E, red) with the median summary denoted
by circles and the 75th percentile summary noted by triangles. The unweighted result
is noted by black squares.
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Figure 3.11: Boxplots of the frequency of falsely finding a null metabolite to be signif-
icant. Each method is presented by a boxplot and each point represents metabolite.
For instance, the exponential weights (E) tend to have low error rates overall, but a
handful of metabolites are called significant up to 500 times. The weight functions are
color coded as before with the median summary in the left box and the 75th percentile
summary in the right box.
3.5 Application
We wish to apply the method of p-value weighting to the motivating data example
of the Sreekumar et al. (2009) [60] metabolite data and matched gene expression data.
We begin by assessing the pathway enrichment of the gene expression data. Two-
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sample t-tests were used to assess the difference of gene expression between localized
prostate cancer and adjacent benign tissues, per gene. All four enrichment methods
(see Section 3.3.1) were then applied. When required, permutation p-values were
calculated from 1000 permutations of the sample labels.
Permutation p-values are limited in precision by the number of permutations used.
Here this resulted in little discrimination of pathways for the two self-contained tests;
binomial and sum of squared statistics. The statistic Sk, however, showed potential
for discriminating between the k pathways.
The results of Simulation I (Section 3.4.1) lead us to favor the CDF weighting
function (D, orange). The results of Simulation II (Secion 3.4.2) show the CDF
weighting function performing well for all but the K-S test. The hypergeometric test
appears to perform best here but it is not robust when the parameter π is reduced
from 0.5 to 0.2, unlike the two self-contained tests, data not shown. Interestingly in
this application Cor(Shyperk , S
SST
k ) = 0.98 across k thus we chose to proceed with the
sum of squared test of enrichment.
In the simulations we set µ̃ = 2 for the CDF function as the presumed differential
effect under the alternative distribution. Yet, the distribution of S̃k across k shows
that this choice may not be optimal; see Figure 3.12. By assigning µ̃ = 2 we may be
severly tempering the upper range of test statistics and thereby reducing the ability
of the weights to differentiate pathway contributions. To assess this we look back at
the data of Simulation II under the sum of squared test. The range of the S̃k values
is less in the simulated data but still suggests that µ̃ = 2 may not be optimal.
Using the first 500 simulated data sets from Simulation II we assessed how varying
µ̃ affected the frequency of detection for each of the 15 simulated differential metabo-
























































Figure 3.12: Distribution of S̃k across k = 1, . . . , 98 pathways in the Sreekumar-matched gene
expression data. Each of the four pathway enrichment tests is shown.
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at first and then decreases as µ̃ becomes large. In contrast the error rates shown in
the bottom panels decrease overall (boxes) but a handful of metabolites are falsely
discovered at increasing rates. It is interesting to note that when a median summary
is used for combining weights for a metabolite in multiple pathways (Figure 3.13
left) the frequency of detecting truly differential metabolites quickly decreases for
a majority of the metabolites. In contrast, if the seventy-fifth percentile is used to
combine the weights across pathways (Figure 3.13 right) then the power loss is less














































































































































































































































































































































Figure 3.13: The effect of adaptive estimation with respect to power in the 15 differential
metabolites (top) and Type I error in the remaining 132 metabolties (bottom). Both
median (left) and seventy-fifth percentile (right) summaries for metabolites involved
in multiple pathways are considered.
From these results we consider assigning µ̃ = P75(S̃), i.e., the 75-th percentile
of the Sk values accross all k. The median 75th percentile, across all 500 simula-
72
tion datasets, is shown with a red dashed vertical line in Figure 3.13. The median
50th percentile (median) is shown by a blue dotted vertical line. The seventy-fifth
percentile appears to be the better choice according to Figure 3.13.
To test this adaptive µ̃ = P75(S̃) we analyzed the remaining 500 Simulation II
datasets. Weight construction used the sum of squares statistic, the CDF weighting
function with µ̃ = P75(Sk) across all k and the seventy-fifth percentile statistic was
used to summarize the pathway weight components (ωk) when a metabolite was
represented in multiple pathways.
Table 3.4: Percentage of times the metabolites are detected to be differential in the
remaining 500 datasets from Simulation II. The fifteen differential metabolites are listed
by the number of pathways (enriched) in which each is included. An adaptive and a
fixed estimation of µ̃ are compared to the unweighted results. Median and maximum
Type I error rates for the 132 non-differential metabolites are given in the bottom rows.
Metabolite µ̃ = P75 µ̃ = 2 Unwt.
5(2) 0.422 0.362 0.3
5(1) 0.568 0.394 0.32
5(0) 0.746 0.408 0.312
4(2) 0.424 0.4 0.312
4(0) 0.066 0.172 0.358
3(2) 0.356 0.37 0.312
3(1) 0.278 0.334 0.288
3(0) 0.23 0.314 0.304
2(2) 0.332 0.372 0.296
2(1) 0.538 0.392 0.292
2(0) 0.236 0.292 0.298
1(1) 0.328 0.368 0.308
1(1) 0.252 0.284 0.34
1(0) 0.694 0.398 0.302
1(0) 0.206 0.298 0.294
Median Error 0.041 0.050 0.050
Max Error 0.104 0.078 0.074
The fixed estimate of µ̃ = 2 shows more consistent, though marginal, increases
in detection rates among the fifteen differential metabolites. The adaptive estimate
of µ̃ = P75(S̃) shows stronger gains but they are balanced by stronger losses. Error
rates are near to the nominal 0.05 rate, however, the adaptive estimate gives a wider
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spread of errors with one metabolite being falsely detected in up to 10.4% of the
datasets.
For the application to the Sreekumar et al. (2009) [60] metabolite data we accept
the potential losses of the adaptive method in favor of the potential for strong gains.
Thus we use the sum of squares enrichment test for gene expression with the CDF
weight function using µ̃ = P75(S̃). Additionally we use the seventy-fifth percentile
summary for metabolites that participate in multiple pathways. The resulting shift



















































































































Figure 3.14: Scatterplot comparing weighted and unweighted p-values for each of the 147
mapped metabolties in the Sreekumar et al. (2009) [60] metabolite dataset. The
matched gene expression data were used to construct the weights.
Twenty-five metabolites were found to be significant at p < 0.05 by both the
weighted and unweighted p-values. There was a loss of eight metabolites by the
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weighted method; homocysteine, asparagine, bradykinin, cysteine, leucine, malate,
N-acetylaspartate, and oxalate. However, there was a gain of ten metabolites result-
ing in a net gain of two metabolites; N-acetylneuraminate, adenine, argininosucci-
nate, aspartate, glycerol, guanosine, hypoxanthine, orotidine-5’-phosphate, spermine
and xanthosine. In the original publication [60] leucine was listed as a metabolite up-
regulated from benign to metastatic disease so this loss is notable. Additionally there
was an enrichment of amino acids detected in the differential metabolites originally
and some are lost with the weighted analysis (e.g. leucine, cysteine) but aspartate is
gained. Finally, sarcosine, which was of primary interest originally, had a decreased
p-value in the weighted analysis (0.029 unweighted; 0.016 weighted) suggesting that
this finding is supported by gene-set enrichment results.
3.6 Discussion
Here we have explored the utility of p-value weighting to enhance the power to
detect differential metabolites. Gene set enrichment scores were used to summarize
the gene expression data. Four enrichment tests of varying style and five weight
functions were considered. As expected, the CDF function (D, orange) is better
suited to the integration of gene expression and metabolite data by pathways than the
exponential function (E, red) which is better suited for strong and sparse regions of
upregulation. The standardized enrichment test statistic (C, purple) also performed
well. Standardization of the enrichment test statistic makes the distribution of the
test statistic better behaved than if the absolute statistic (B, blue) were used directly.
However, the CDF function of the standardized test statistic is more robust when the
tails of the per-gene test statistics are long. The p-value weight (A, green) performed
well in Simulation I (Section 3.4.1) but had mixed results in the more complex second
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simulation (Section 3.4.2). In contrast, the absolute test statistic (B, blue) performed
very poorly in Simulation I but performed moderately well in the second simulation.
Considering both simulations we recommend using the CDF function (ωk = Φ(S̃−
µ̃), with S̃ = S−E(S0)√
V ar(S0)
and µ̃ = 2) when the distribution of the per-gene test statistics
has long tails. Alternatively, a thresholded enrichment test can be used which ignores
the magnitude of the per-gene test statistics by classifying each test as differential
or not. In application we discovered that the use of µ̃ = 2 may not be optimal and
an adaptive method for estimating µ̃ was explored. This adaptive method produced
more consistent gains for some differential metabolites but also resulted in more
severe losses. The choice of a fixed or adaptive µ̃ should be made in consideration of
the study goals.
When a continuous enrichment test is desired, we prefer the self-contained sum of
squared statistic test to the weighted Kolmogorov-Smirnov (K-S) test. This may be
the difference between a self-contained and a competitive test for the application of
summarizing gene expression information for constructing weights. Alternatively, the
weighted K-S test has been receiving poor reviews in the recent literature (e.g. Ack-
erman and Strimmer, 2009) so perhaps a different continuous-measure competitive
test would have better performance.
Another appealing feature of the p-value weighting method is that all metabolites
can be considered in the analysis. Currently, as few as one third of the metabolites
measured are identified (Sreekumar, 2009). As mass spectrometry libraries are ex-
panded this number will increase but those metabolites that are unknown or are not
mapped to gene expression are simply awarded a weight of 1. This does not adjust
the p-value nor does it affect the requirement that the weights average to 1. Thus
the unidentified metabolites are tested as they would have been had weighting not
76
been considered.
Moving forward, we plan to explore other methods of summarizing the gene ex-
pression data to construct weights for the metabolites. Combining the data on a
pathway level can lose power as the number of pathways to which the metabolite be-
longs increases. We are thus working on a method to summarize the gene expression
information on a per-metabolite basis.
We additionally considered two weighting functions that include the metabolite
data in the weight. The appeal of these weight functions is that the gene expression
information would not be allowed to dominate the metabolite data. Expanding
on the grouped weight method of Roeder et al. (2006) [53] we define groups using
the metabolic pathways and the weight as a mixture of the estimates of gene set
enrichment and metabolite enrichment. We hoped that inclusion of external gene
expression information would reduce the bias of an internal weight since the number
of metabolites per group is often smaller than the twenty recommended by Roeder
et al. (2006) [53] to engage the sieve principle. We used either the percentage of
metabolites measured per group or the correlation between the gene expression and
the metabolite data to determine the mixing parameter. However, in simulation
this method produced inflated type I error rates for both weight functions and the
method was abandonded. For clarity details are omitted here but interested readers
can see Appendix B.
CHAPTER IV
Integrative pathway enrichment testing methods for joint
assessment of multiple omics platforms
4.1 Introduction
In case-control studies we are interested in comparing two groups of samples on
a collection of measured variables possibly associated with case status. When the
variables of interest are measurements from a high-throughput molecular assessment,
such as from a gene expression microarray, the result is thousands of comparisons.
The resulting list of differential genes can be unwieldy with hundreds of entries.
Given this, researchers are often interested in grouping these lists into sets of genes
with common functionality. The area of enrichment testing looks at an a priori
defined gene set, such as from KEGG (Kyoto Encyclopedia of Genes and Genomes)
or GO (Gene Ontology), and asks if the number of differential genes in the set is
remarkable; either more or less than expected.
When the high-throughput assessment is metabolomics the number of molecules
measured is reduced by at least an order of magnitude compared to gene expression
assays [60, 70]. But the list of differential molecules can still be lengthy with respect
to the number of leads feasibly followed. Thus, the desire to elucidate common
functional patterns remains. The pitfall with a smaller list is that the sets of interest
may not be represented well for testing. For instance, if three molecules are measured
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from a given set and two are differential this is 67% enrichment but it may not be
statistically significant and it is not clear if it is biologically interesting.
Enrichment tests work by assessing the overall evidence of differential behavior
of the elements (e.g. genes, metabolites) within the set. Tests that do not depend
on dichotomizing the elements, into differential and not, are able to incorporate
even moderate changes [64]. When we have measured many molecular aspects, e.g.
gene expression, metabolites, proteins, it seems beneficial to assess their differential
tendencies jointly across platforms. Integration of omics technologies has proved
to be beneficial in other areas resulting in more interpretable results [45] and more
meaningful associations [17] than when the platforms are assessed separately. In
an effort to translate this success to the area of set enrichment we explore two set
enrichment tests and describe methods for their multivariate application.
We begin with an overview of enrichment testing theory in Section 4.2. The
methods of interest are described in Section 4.3 and the multivariate extensions are
detailed. We explore the properties of these methods by simulation as detailed in
Section 4.4. A metabolomics dataset [60] and related gene expression dataset [68]
are used in Section 4.6 for an application of the top methods to existing data. We
conclude with discussion and recommendations in Section 4.7.
4.2 Background on Enrichment Testing
Recently enrichment testing methods have been classified into two general flavors;
competitive and self-contained [24, 48, 64]. Additionally two resampling methods are
commonly used to assess the null hypotheses of these models [48]. In this section
we introduce these testing styles and their underlying null hypotheses. We describe
the resampling methods used for estimating the null distribution of the test statistic
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Table 4.1: The general scheme for a hypergeometric test of differential genes A set of G
genes is divided by the criteria of inclusion in the set of interest (S) and inclusion in the
set of differential genes (D).
Differential Non-differential
gene (D) gene (D′) Total
In the set (S) GSD GSD′ GS
Not in the set (S′) GS′D GS′D′ GS′
Total GD GD′ G
and discuss the pros and cons of each method. For clarity the following discussion
will use gene expression as the omics platform of interest, however these methods
are applicable to any omics platform whose elements can be classified into a priori
defined sets.
For reference we define the 2×2 classification depicted in Table 4.1. Here G genes
have been individually tested for differential expression, perhaps using two-sample
t-tests per gene. An interesting set of genes S has been defined. We can classify each
of the G genes by whether they are differential (D) and whether they are in the set
of interest (S).
4.2.1 Competitive Tests
For a set of genes, S, a competitive test assesses whether the amount of differential
expression differs from that of its complement S ′. The competitive null hypothesis,
Hcomp0 , then assumes that
Hcomp0 : genes within the set S show the same amount of association with
the phenotype as those in set S ′
[64, 24]. In this way each gene set competes against its complementary set of mea-
sured genes.
A popular competitive set enrichment test is the Fisher’s Exact test run on Table




In set A 4 4 8
In set B 6 2 8
Total 10 6 16
D D′ Total
In set A 4 4 8
In set C 2 6 8
Total 6 10 16
Table 4.2: An example of the relative estimation problem in competitive tests Consider
testing a set A in which half of the genes are differential (D). Table (i) uses set B as the
reference set and table (ii) uses set C as the reference group, where sets B and C switch
labels D and D’.
significant result suggests that the rate of differentially expressed genes is associated
with pathway status. Specifically, we test that Pr(GSD 6= gSD|GS = gs, GS′ =
gS′ , GD = gd), assuming GSD ∼ Hyper(GS, GS′ , GD), where GSD, GS and GS′ are
defined as in Table 4.1. As it is a two-sided test, a detected association may be
due to enrichment or depletion of differential genes. The Fisher’s Exact test is a
competitive test in that it uses information on the differential expression of genes
not in the set.
The chief complaint against enrichment tests based on relative enrichment estima-
tion is that the significance of a set S can differ depending upon the gene sets used
for the reference set S ′ [2]. Consider the gene sets A, B, and C as depicted in Table
4.2.1. Each of the three sets has eight genes with 50%, 75%, and 25% enrichment,
respectively. If we compare set A to set B, as in Table 4.2.1i, then the one-sided
hypergeometric test is Pr(GAD > 4|G = 16, GD = 10, GA = 8) = 0.69. However, if
we compare set A to set C, as in Table 4.2.1ii, then the one-sided hypergeometric
test is P (GAD > 4|G = 16, GD = 6, GA = 8) = 0.06. Clearly the significance of
the enrichment in set A is affected by the reference set though the number of genes
called differential in set A does not change.
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Though viewed as a limitation, critics concede that relative estimation is useful
when there is a large number of genes that are differential, as when comparing cancer
versus normal tissue [24, 48]. In essence, competitive test results can be used to rank
a series of gene sets of interest thereby distinguishing potentially interesting results
from those arising by chance.
An additional argument against competitive testing is that most rely on gene-
resampling to generate the null distribution [48, 24]. Essentially we can rewrite
Hcomp0 to say that S has as many differential genes as if they were drawn by chance
from the set of all genes, S ∪ S ′. Empirical estimates of the null hypothesis are then
generated by randomly sampling GS genes from S ∪S ′ and repeating the test on the
random set S∗.
Arguments against gene-resampling methods are three-fold: lack of independence
between genes, improper p-value interpretation, and sample size inflation. First, un-
der gene-resampling we assume that the genes are independent with no distinction
other than the label of differential (D) or not, (D′). However, we know that it is
not accurate to assume that the expression levels of the full complement of genes
are independent. Thus, it is possible that evidence against the null hypothesis ac-
tually reflects the underlying correlation structure of the genes and does not reflect
a true enrichment of differential expression [64]. One may argue that identification
of strongly correlated genes may also be valuable but it is important to understand
that this may arise.
The second criticism of gene-resampling methods, as pointed out by Goeman
and Bühlmann (2007) [24], is that the generated p-value must be interpreted in
the context of gene sampling. We define a p-value to be the probability that a test
statistic as extreme, or more, is observed when the experiment is repeated hundreds of
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times and the null hypothesis is true. Under a gene sampling scheme the experimental
unit becomes the gene and the p-value indicates confidence that a new set of genes
would show similar association with the set of interest. No claims can be made,
however, about the association should a new set of biological samples be procured.
Finally, when constructing a test based on gene sampling, the “sample size” be-
comes the number of genes, G, which is often larger than the number of biological
samples by a few orders of magnitude. This leads to sample size inflation and an in-
flation of power [24]. In an extreme example, Breitling et al. (2004) [7] claim that the
2x2 table can be used to produce meaningful statistical results with only a single pair
of biological samples — one case and one control — used to determine differential
genes, say through a thresholded ranked list of ratios.
4.2.2 Self-contained Tests
In contrast to competitive tests, self-contained tests do not utilize S ′ in the as-
sessment of S. Specifically, we consider only the first row of Table 4.1 and ignore the
second row. The self-contained null hypothesis, Hsc0 , assumes that
Hsc0 : the gene set S does not contain any genes whose expression levels
are associated with the phenotype of interest
[64, 24].
In a simple example, we can test the cell GSD in Table 4.1 using a binomial test
of proportions based on GSD ∼ binomial(GS, α), where α is an expected rate of
differential genes which can be set to zero or the expected error rate, say α = 0.05.
Notice that, contrary to the relative estimation of the competitive hypergeometric
test, this self contained binomial test gives the same p-value for both Table 4.2.1i and
Table 4.2.1ii. Specifically, the one sided test of Pr(GAD > 4|GA = 8, α = 0.05) =
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1.5× 10−5.
An additional benefit of testing Hsc0 is that it reduces well so that gene sets of
size one are treated as a differential expression test. At the other extreme it can
be used as a global test of differential expression using the entire microarray as
the set of interest [24]. Arguments against self-contained tests focus on the strong
null hypothesis in relation to its biological interpretation. In particular, a single
differential gene may be able to give enough evidence to reject the null hypothesis
depending upon the differential threshold used and the number of genes in the set,
however, this may not represent a biologically interesting result [24].
In their favor, self-contained tests primarily utilize subject-resampling methods
rather gene-resampling to determine the null distribution of the test statistic [48].
Subject-resampling assumes that the subjects are independent and that under the
null hypothesis the sample labels are meaningless and could have been assigned
randomly. Permutation testing is a common method of subject-resampling in which
the diagnostic class labels are shuffled between subjects and the test is repeated
under the new assignment.
In contrast to gene-resampling, subject-resampling follows the experimental de-
sign of most studies by assuming that the subjects are independent realizations of the
study population. By sampling the subjects the between-gene correlation structure
is maintained. Additionally, the sample size is reflective of the number of subjects
included and the p-value is generalizable to experiments with new subjects under
study.
Subject-resampling tests are not without objection though. First, while gene
sampling methods exaggerate the sample size, subject-resampling tests are limited
by their often small sample size. In this way, p-values derived from permutation
84
testing may be coarse and the level of discrimination desired may not be available
[2, 48]. Second the null hypothesis being tested by subject sampling may be more
difficult to state, especially when it is used to assess competitive tests (see Section
4.2.1).
4.2.3 Other Tests and Recommendations
Nam and Kim (2008) [48] suggest that there is a third test style which uses a
null hypothesis intermediate to Hsc0 and H
comp




Hmixed0 : none of the gene sets considered is associated with the phenotype
[44]. In essence it is a simultaneous test of all gene sets. Hmixed0 is used by the GSEA
test [44, 61] and the GSA test [13]. However, rejection of Hmixed0 only implies that
there is at least one set that is associated with the phenotype. Further steps are
required to make set-wise assessments.
Goeman and Bühlmann (2007) [24] note that tests of Hsc0 are more sensitive than
Hcomp0 for detecting changes within a set. However, Nam and Kim (2008) [48] show
by simulation that tests of Hsc0 are not specific. The recommendation of Nam and
Kim (2008) [48] is vague such that a test should be chosen according to the interest
of the study, relying on Hmixed0 as a moderate choice, but preferably testing all
three hypotheses simultaneously when possible as they each address slightly different
questions.
With respect to sampling methods, Nam and Kim (2008) [48] suggest that gene-
resampling methods be used when sample sizes are small. In contrast, Allison et
al. (2006) [2] suggests that both subject sampling and gene sampling methods be
considered as they are testing different hypotheses. Finally, some authors suggest a
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compromise that incorporates features of both gene sampling and subject sampling
such as in Erfon and Tibshirani (2007) [13]. In this work we consider both competi-
tive and self-contained methods. Gene-resampling and subject-resampling are used
according to the null hypothesis of the test.
4.3 Joint Assessment of Enrichment
We consider conducting tests of enrichment that incorporate both the gene ex-
pression and metabolite information. We begin with per-gene and per-metabolite
assessments of differential ability. Thus we have two vectors of test statistics, TG =
(TG1 , T
G
2 , . . . , T
G
g ) and T
M = (TM1 , T
M
2 , . . . , T
M
m ), and their corresponding p-values,
PG = (PG1 , P
G
2 , . . . , P
G
j ) and P
M = (PM1 , P
M
2 , . . . , P
M
j ), for the g genes and m
metabolites, respectively.
The univariate tests can be employed as a means of joint assessment by simply
concatenating the per-gene and per-metabolite test statistics to form a single vector
of data, e.g. T = (TG, TM). However, concatenation of the lists may lead to bias
favoring the larger dataset [59]. Additionally, the joined vectors must be made com-
parable before concatenation. For instance, if the different platforms have different
sample sizes, NG 6= NM , then two-sample t-tests per-element will not be comparable
as they have different degrees of freedom. Concatenating lists of p-values will resolve
this problem as they are comparable by design. However, p-values may not be as
precise if they were determined by empirical distributions and they lose directionality
that may be of interest.
Enrichment can be assessed separately for each of TG and TM and then combined
by considering intersections and unions of the individual enrichment test results.
This method may help with ranking sets of interest since sets that are enriched
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independently by both platforms are likely to be of interest. However, it does not
benefit by sharing of strength between the platforms. To arrive at a single statistic we
can join the two results using a p-value combining method such as Fisher’s method
[46]. Here we assume that −2× (logePMS + logePGS ) ∼ χ24 for the enrichment p-values
for metabolites and genes in set S. However, the χ2 distribution is not correct when
the tests being summed are dependent [73] which is likely the case here.
In the following we propose multivariate extensions of two univariate tests that use
the information from each platform to form a single test of enrichment. As described
below, we consider extending the competitive logistic regression test of Sartor et al.
(2009) [57] and the self-contained sum of squared statistics [1]. We compare our
multivariate extension to the univariate tests of each platform, the univariate test of
concatenated datasets, and the sum of p-values in Section 4.4.
4.3.1 Competitive test: Logistic regression analysis with 2-df Wald test
Logistic regression was introduced by Sartor et al. (2009) [57] as an alternative
test to the Fisher’s Exact test which does not require dichotomization of the genes
into differential and not. The logistic model proposed by Sartor et al. (2009) [57] is
logit(Pr(Gj ∈ S)) = γ0 + γ(−log10(pGj )) where pGj is the p-value from the per-gene
test of differential expression for gene j. The test ofHLR0 : γ = 0 can be obtained from
standard statistical software using a 1-degree of freedom Wald test where rejection of
HLR0 indicates enrichment or depletion of the set. This is a competitive test because
it takes an indicator of the genes inclusion in the set of interest, S, as the dependent
variable, thereby comparing genes in S to all other genes, i.e. S ′.
For the joint assessment we begin by modelling the genes and metabolites sep-
arately using the absolute value of the per-element t-statistic as the measure of
differential ability. We chose to use the absolute t-statistic instead of −log10(p) be-
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cause it appeared to be more stable in bootstrap resampling described below. Thus
for set S we fit the following two models:
(4.1) logit(Pr(Gj ∈ S)) = γ0 + γ(|TGj |)
(4.2) logit(Pr(Mk ∈ S)) = µ0 + µ(|TMk |).
We construct a joint test of HLR02 : γ = 0, µ = 0 using a two degree-of-freedom
Wald test. Specifically, EV −1ET , where E = [γ̂, µ̂], and V is an estimated variance-
covariance matrix for γ and µ. We can obtain estimates of the variance of γ and µ
from the univariate model estimates. However we do not have a convenient estimate
of the correlation between the two parameters.
To estimate the correlation between the esimates γ̂S and µ̂S, for pathway S, we
construct the bootstrap distributions of the two parameters, say γ̃ = (γ̃1, γ̃2, . . . , γ̃B)
and µ̃ = (µ̃1, µ̃2, . . . , µ̃B). We use row-resampling which reflects the use of genes and
metabolites, not subjects, as input into the model. Through simulation we found
that subject-resampling, which does not reflect the use of genes and metabolites as
input into in the logistic regression model, dramatically underestimates the variance
of the parameters compared to the variance estimates obtained from the univariate
models of Equations 4.1 and 4.2. Additionally, when resampling the elements, we
stratify the sample by inclusion in S to retain a fixed number of elements in S in
each bootstrap sample. That is, for the set S we can split TG into TGS and TGS
′
.
We sample n(SG) genes from T
GS with replacement, where n(SG) is the number of
genes in S. The remainder of the genes are sampled with replacement from TGS
′
.
The metabolite test statistics are then resampled in the same fashion. Stratification
is especially important for platforms that tend to have small set counts.
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Upon generation of B bootstrap estimates of γ and µ, γ̃ = (γ̃1, γ̃2, . . . , γ̃B) and
µ̃ = (µ̃1, µ̃2, . . . , µ̃B), we can compute an estimate of the correlation ργµ =corr(γ̃, µ̃).
To reduce convergence error associated with small samples sizes and logistic regres-
sion bootstrapping we use a one-step bootstrap procedure as described by Moulton
and Zeger (1991) [47]. Essentially the iterated weighted least-squares (IWLS) esti-
mation algorithm is seeded with the observed parameters values of (γ̂0, γ̂) for the
gene expression. Then, given the bth bootstrap resampled vector TGb, one step is
taken in the IWLS algorithm and the new estimate (γ̃0
b, γ̃b) is reported. The IWLS
algorithm is stopped here and not allowed to continue to convergence. One-step
estimation is particularly important for models on small sets where the full IWLS
can have problems of separation resulting in estimates nearing positive or negative
infinity. Such non-convergent estimates inflate the variance and in simulation the
variance estimates tended to be large compared to their model based counterparts
with some variances on the order of 103 and greater when n(S) = 4.
Through simulation we find that there is not strong correlation between the pa-
rameters γ̂ and µ̂ even in sets where the genes and metabolites were simulated to
be correlated. Figure 4.1 shows a histogram of N correlation estimates, each from
B = 500 bootstrap resamples, for a set S in which there is correlation between
genes, ρGG = 0.6, between metabolties, ρMM = 0.6, and between genes and metabo-
lites, ρMG = 0.25. The correlation in S
′ is not homogeneous and most genes and
metabolites are simulated to be independent. These correlations are defined further
in Section 4.4.2 where we have described our model for simulating data.
We see in Figure 4.1, i that the distribution of the estimates are fairly symmetric
about zero. If we perform Fisher’s transformation on the correlations to arrive at
standardized z-scores we see that the estimates are underdispersed compared to the
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Figure 4.1: Correlation of γ and µ (i) Correlation of the estimates of γ and µ do not differ much
from zero. (ii) They are under-dispersed compared to the expected normal distribution
under the Fisher’s z-score transformation.
quantiles of a standard normal distribution; see Figure 4.1, ii. The loss of correlation
is likely due to the row-resampling that is used for this bootstrap.
Given these findings, we assume that the correlation is zero between γ̂, and µ̂
for all sets. Thus V can be estimated as a diagonal vector with var(γ̂) and var(µ̂)
estimated from the univarite models. This reduces our test statistic to the sum of
the two one-degree-of-freedom tests. Specifically, the test statistic for set S can be
written as ULRS = EV
−1ET = γ̂2σ−2γ +µ̂





We assume that ULRS ∼ χ22 under the null hypothesis HLR02 : γ = 0, µ = 0.
4.3.2 Self-contained test: Sum of squared statistics with 2-dimensional permutation
test
We begin with the test statistics measuring the differential ability TG = (TG1 ,
TG2 , . . . , T
G
g ) and T
M = (TM1 , T
M
2 , . . . , T
M
m ), for each gene and metabolite, respec-
tively, separately. This enrichment test is simply the sum of all squared test statistics





2I(j∈S), for j = 1, . . . , g genes and I(a) is an indica-
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tor function where I(a) = 1 if a is true and 0 otherwise [1]. The statistic W
M
S for
metabolites can be defined equivalently. Significance of WGS and W
M
S is determined
separately by generating the null distribution for each using permutation of sam-
ple labels to form null datasets. Notice that this is a self-contained test as it only
depends on the elements in the S but not S ′.
To obtain a two-dimensional test we must decide on a way to assess how ex-
treme the observed statistics (WGS ,W
M
S ) are when compared to each pair of null
estimates (W̃GS , W̃
M











S )h ≥ ŴMS ) for
metabolites. For a multivariate application we calculate the Mahalanobis distance
from the observed statistics (ŴGS , Ŵ
M
S ) to the centroid of the cloud of permutation
statistic pairs.














S )− 1(ψGH , ψMH ))
where (ψGH , ψ
M




S ) and VH is their
variance-covariance matrix [11]. The vector 1 is anH×1 vector of 1s. Given (ψGH , ψMH )
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including the observed pair (ŴGS , Ŵ
M
S ). Thus to calculate the joint permutation
p-value for (ŴGS , Ŵ
M










S )h ≥ DSH(ŴGS , ŴMS )).
Figure 4.2 gives an example of the application of the Mahalanobis distance. Here




































































































































































Squared Mahalanobis distances, n=100, p=2





Figure 4.2: Mahalanobis Distance (i) A contour plot overlaying the scatterplot of 100 random
draws from a bivariate normal distribution with mean zero, unit variance, and 50%
correlation. The centroid defined by the marginal means is noted by a blue square.
Three points of interest are added as the red triangle, orange diamond and purple circle
(ii) The distribution of the Mahalanobis distance from the centroid for each point in
the scatter with the three new points highlighted. Their rank can be used to determine
a p-value.




y = 1, σxy = 0.5). This hypothetical null distribution
is plotted with black circles in Figure 4.2i. The centroid (ψx, ψy), determined by
marginal means, is highlighted by a blue square. Though, in practice, each observed
pair of statistics would have a unique null distribution, we suggest three possible
observed pairs plotted here by a red triangle, purple circle, and orange diamond.
We chose to use the Mahalanobis distance metric since it accounts for the shape
or spread of the null distribution [11]. The utility of this become apparant when we
calculate the permutation p-values for each of the three hypothetical observations.
Figure 4.2ii provides a distribution for the distances of the null values (black circles)
from the centroid (blue square). The distance of each of the three hypothetical
observations to the centroid is marked by a like-colored vertical line. The orange
diamond, being near to the centroid (blue) is surpassed by most null values resulting
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in a p-value of 0.94. The red triangle is on the edge of the null distribution but is
still surpassed by a few null points so it is given a p-value of 0.04. The purple circle
is outside of the cloud of null points and thus results in a p-value < 1/H, where H
is the number of permutation datasets used.
Points such as the hypothetical purple observation in Figure 4.2 are of most in-
terest because they would be missed marginally. Additionally, had we not accounted
for the non-spherical shape of the null distribution, such as by using an Euclidean
distance measure, E(x, y) = (((x, y) − (ψx, ψy))T ((x, y) − (ψx, ψy)))1/2, the purple
point would not have been identified as extreme.
4.4 Simulation Models
We use simulation to assess the properties of our multivariate enrichment tests and
to compare them to various univariate methods. Two simulation models are used.
Each will be described in turn and results will be presented in the following section.
The pathway maps of the Kyoto Encyclopedia of Genes and Genomes (KEGG, [35,
36, 34]) were used as motivating examples; see also Appendix A. Thus in the following
we will use the term “pathway” instead of “set” to indicate an a priori defined
collection of genes and metabolites.
4.4.1 Disjoint Pathway Simulation
In this simulation model we assume that the genes and metabolites can be sep-
arated into fifty disjoint pathways. That is any gene or metabolite is included in
only one pathway. The correlation structure is the same for each pathway but no
correlation is assumed between pathways. Additionally, ten pathways are simulated
to have association with disease and the level of enrichment is consistent across these
pathways. This simple model with homogeneous pathways allows us to explore very
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specific hypotheses about the properties of our methods.
Let Yij be the gene expression measurement for sample i and gene j. Likewise let
Zi′k be the metabolite intensity measure for sample i
′ and metabolite k. The gene
expression measures and metabolite measures need not arise from the same subjects,
but it is possible for some or all samples to be matched by subject, i.e. i = i′. Define






We assume the data, Y and Z, can be sorted into P pathways. Let Ip be an





Furthermore, define the indicator variables gjp and mkp for the inclusion of gene j
and metabolite k, respectively, in pathway p,
gjp =





1 Metabolite k in pathway p
0 otherwise
Define Dj and Ck as indicator variables of differential gene expression and dif-
ferential metabolite intensity, respectively, between cases and controls. We can use
pathway association to define Bernoulli distributions for Dj and Ck such that a gene
or metabolite has a chance d1 or c1 of being differentially expressed provided that
it is in at least one associated pathway, i.e. maxp(Ipgjp) = 1 and maxp(Ipmkp) = 1,
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respectively for genes and metabolites.
Dj ∼





Bern(c1), maxp(Ipmkp) = 1
Bern(c0), otherwise
Here d1, d0, c1, and c0 are fixed values and can be adjusted in simulation. To simulate
pathway enrichment we assign d1 > d0 and c1 > c0. Interestingly, as d1 → d0 (or
as c1 → c0) the effect of being in the pathway diminishes under the competitive
definition of enrichment because no pathway will be enriched above its complement.
However, this is not a concern for tests of the self-contained null hypothesis provided
that d1 and c1 are still sufficiently large, since they do not consider the elements in
the complement of the pathway
Let us then write the simulation model as:
(4.6)
Yij = α + βj + ωjD(Ipgjp)jWi + eYij
Zi′k = θ + φk + ηkC(Ipmkp)kWi′ + eZi′k
This additive model allows for a non-zero global mean expression (intensity) level
through α (θ). It assumes a mean expression (intensity) level per gene (metabolite)
as defined by βj (φk) which is modified for case samples by ωj (ηk) according to
the distributions D(Ipgjp)j (C(Ipmkp)k). We allow eYij and eZi′k to be correlated,
ρmg, in order to simulate matched samples. We also allow correlation between genes
ρgg = Corr(eYij , eYij′ ) and between metabolites ρmm = Corr(eZi′k , eZi′k′ ). In this
simulation model these correlations are limited to genes and metabolites within the
same pathway, thereby reducing the complexity of the simulated data structure.
The simulation of the data is then as follows:
1. Determine sizes Ngene, Nmetabolite, Nsample, Npathway
2. Determine case status Wi, i = 1, . . . , Nsample, fixing Ncase and Ncontrol
95
3. Determine pathway associations Ip, p = 1, . . . , Npathway, fixing Nassoc and path-
way memberships gjp and mkp.
4. Determine correlation terms ρg,g, ρm,m, and ρm,g.
5. Jointly simulate the gene expression data matrix (size Ngene×Nsample) and the
metabolite data matrix (size Nmetabolite ×Nsample)
(a) Assume data is globally standardized per sample, α = 0 and θ = 0.
(b) Draw variance terms σ2Yj ∼ χ
−2
4 , for j = 1, . . . , Ngene and σ
2
Zk
∼ χ−24 , for
k = 1, . . . , Nmetabolite.
(c) Draw element-wise mean terms βj ∼ N(0, 4σ2Yj ), for j = 1, . . . , Ngene and
φk ∼ N(0, 4σ2Zk), for k = 1, . . . , Nmetabolite.

































and σ·· is chosen to retain the desired correlation ρ··.
6. Apply differential effects
(a) Draw mean effect sizes ωj ∼ Unif([−2.5,−0.5] ∪ [0.5, 2.5]), for j = 1, . . . ,
Ngene and ηk ∼ Unif([−1.5,−0.5] ∪ [0.5, 1.5]), for k = 1, . . . , Nmetabolite.
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(b) For fixed d1, d0, c1, and c0 draw Dj ∼ IpgjpBern(d1) + (1− Ipgjp)Bern(d0)
and Ck ∼ IpmkpBern(c1) + (1− Ipmkp)Bern(c0)
(c) Set yij = y
′
ij + ωjDjWi and zi′k = z
′
i′k + ηkCkWi′
For this simulation, we assume that the number of samples is the same for cases
and controls, with Nsample ∈ (30, 100). We allow the correlations to vary: ρY Y =
ρZZ ∈ (0.2, 0.6) and ρY Z ∈ (0.10, 0.25) where ρY Y = ρZZ > ρY Z . We consider
gene pathways with 20 measurements, i.e. NGp = 20, and metabolite pathways with
NMp ∈ (4, 20). The enrichment levels (d1, d0) and (c1, c0) are allowed to vary with
(d1, d0) = (c1, c0) ∈ [(0.5, 0), (0.25, 0), (0.10, 0), (0.25, 0.05), (0.05, 0.05), (0.10, 0.10),
(0, 0)] with the last three pairs representing null models.
4.4.2 Varying Pathway Simulation
This simulation model generates the same number of genes and metabolites in
total and per-pathway as for the disjoint simulation above. The simulation model
of Equation 4.6 is used as the basis of the data generation. However, mkp, gjp,
Dj, and Ck are fixed to construct clusters of genes and metabolites with varying
levels of association with disease. We also allow the pathways to overlap and to be
non-homogeneous in correlation structure and enrichment. This style of simulation
was used by Ackermann and Strimmer (2009) [1] in their review of various single-
platform enrichment tests. Here we can assess how well the methods are able to
detect various pathway types in a non-homogeneous setting. Null pathways are also
included providing a reference set for competitive tests and allowing us to estimate
false discovery.
The Ngene × Nsample gene expression matrix and Nmetabolite × Nsample metabolite
intensity matrix are drawn in blocks of NGp × Nsample genes and NMp × Nsample
97
Table 4.3: The data are generated from 10 multivariate distributions with the following
correlation structures and differential patterns. Twenty genes and four metabolites are
drawn from each distribution (h = 1, . . . , 9). Background genes (n=820) and metabolites
(m=164) are simulated to be non-differential and without correlation, see distribution
h = 0.
Distribution (h) 0 1 2 3 4 5 6 7 8 9
% Differential Genes 0 100 100 100 100 100 100 0 0 0
% Differential Metabolites 0 100 100 100 0 0 0 100 100 100
ρY Y , ρZZ 0 0 r1 r1 0 r1 r1 0 r1 r1
ρY Z 0 0 0 r2 0 0 r2 0 0 r2
metabolites according to multivariate normal distributions h = 1, . . . , 9; see Table
4.3. These 9 distributions have varying levels of correlation and enrichment between
genes and metabolites. The remaining genes and metabolites required to reach size
Ngene and Nmetabolite, respectively, are drawn from distribution h = 0 to represent
the null elements.
The data are simulated as follows:
1. Set Ngene, Nmetabolite, Nsample, and Ncase, where Ncontrol = Nsample −Ncase.
2. Assume data is globally standardized per sample, i.e. α = 0 and θ = 0.
3. For each gene j, j = 1, . . . , Ngene, and each metabolite k, k = 1, . . . , Nmetabolite










(c) draw mean effect sizes ωj ∼ Unif([−2.5,−0.5] ∪ [0.5, 2.5]) and
ηk ∼ Unif([−1.5,−0.5] ∪ [0.5, 1.5]).
4. Jointly draw yij and zik from each of the ten multivariate normal distributions
(h = 0, 1, . . . , 9, see Table 4.3). Specifically,
(a) for distribution h ∈ (1, 2, 3) containing NGp genes and NMp metabolites,
draw Ncontrol control samples from (yi, zi)h ∼ MVN((β, φ)h,ΣhY Z), and
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and (ρgg, ρmm, ρmg) are defined in Table 4.3.
(b) for distribution h ∈ (4, 5, 6) containing NGp genes and NMp metabolites,
draw Ncontrol control samples from (yi, zi)h ∼ MVN((β, φ),ΣhY Z), and
Ncase case samples from (yi, zi) ∼MVN((β+ω, φ)h,ΣhY Z), where ΣhY Z is
as defined above.
(c) for distribution h ∈ (7, 8, 9) containing NGp genes and NMp metabolites,
draw Ncontrol control samples from (yi, zi) ∼ MVN((β, φ)h,ΣhY Z), and
Ncase case samples from (yi, zi) ∼ MVN((β, φ+ η)h,ΣhY Z) where ΣhY Z is
as defined above.
(d) for distribution h = 0 containing Ngene − 9 × NGp genes and Nmetabolite −
9×NMp metabolites, draw Nsample samples, that is for ncases and ncontrols,
from (y
i




= diag(σ2Y , σ
2
Z)h.
As in the disjoint simulation, Section 4.4.1, we setNGp = 20 andNMp to be either 4
or 20. This results in 1000 genes and either 200 or 1000 metabolites, according to the
simulation parameters. The data are correlated for some genes and some metabolites,
though not all are correlated, see Table 4.3. The overall rate of differential expression
is 12% for the genes and 12% for the metabolites in each dataset.
To assess various pathway structures we subset these data into various “pathways”
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Table 4.4: Simulated pathways to be tested for enrichment. Each pathway p contains NGp
genes and NMp metabolites drawn such that π- percent of the elements are from a
differential distribution h ∈ (1, 2 . . . , 9) and the remainder are from the null distribution
h = 0.Pathways 25–29 are constructed by random draws across all 10 distributions,
h ∈ (0, 1, . . . , 9). Pathways 30 – 70 are a disjoint partition of the null set, h = 0, so that
each element in this set contributes to at least one pathway.
π Distribution (h) 1 2 3 4 5 6 7 8 9
1 1 2 3 4 5 6 7 8 9
0.5 10 11 12 13 14 15 16 17 18
0.25 19 20 21 22 23 24 - - -
of interest. In particular, we are interested to know how well each test can find
the 24 pathways described in Table 4.4. We also construct five random pathways,
i.e. pathways 25-29, where the pathway membership is a random draw from all
simulated genes or metabolites. These five pathways allow us to consider the rate
of non-specific pathway identification since genes and metabolites are selected across
all distributions h = (1, 2, . . . , 9). Finally, the remaining 41 pathways, i.e. 30–70,
are a partitioning of the null elements, h = 0, so that each element participates in
at least one pathway. The null pathways allow us to look at false discovery error
rates. The pathway participation indicators, gjp and mkp for pathway p, gene j and
metabolite k, respectively, are determined at the start of the analysis. Random draws
as required for pathways 10 - 29 are done once so that pathway membership is not
changing throughout the analysis since we would not expect this in application to
non-simulated data.
For clarity, an example of the indicator matrix, mkp, for the inclusion of metabolite
k in pathway p, is given in Table 4.5. This matrix represents a dataset of 200
metabolites assigned to 70 pathways of size NMk = 4. Notice that accoring to Table
4.4, 100% of the metabolites of pathway p = 1 are drawn from distribution h = 1.
Likewise 50% of the metabolites in pathway p = 10 are drawn from distritubion
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h = 1 and 50% are drawn from h = 0. The randomly drawn pathways p = 25
and p = 29 are shown. Notice that pathway p = 25 does not include any of the
differential metabolites, k ∈ (1, . . . , 36), where as one differential metabolite, k = 4,
was selected to be included in pathway p = 29. Pathways p ∈ (30, . . . , 70) are formed
by a partitioning of the null metabolites, h = 0 and k ∈ (37, . . . , 200).
4.5 Simulation Results
Using the simulation models above we explored several enrichment testing meth-
ods. We are particularly interested in the two multidimensional methods that we
devised; the 2-df Wald test for logistic regression and the 2-dimensional permutation
test for the sum of squared statistics. For comparison we also considered the univari-
ate counterparts for these methods testing enrichment based on the genes alone and
on the metabolites alone. We also consider joining the data via concatenation and
joining the tests via Fisher’s method of combining p-values, abbreviated in figures a
“p-sum”. Each of these methods is described in Section 4.3. Finally, given its contin-
ued popularity, we also consider the Fisher’s Exact test, though no multi-dimensional
extension was devised.
4.5.1 Varying pathway simulation results
Let us first consider some results from the variable pathway simulation of Section
4.4.2. These simulations provide an overview of the behavior of the methods. For
each simulation scenario, 100 datasets were generated and tested. In Figures 4.4 and
4.5 we depict the frequency with with each pathway, from 1 – 29, was determined to
be significant at α = 0.05 for each test considered. The symbol key for these plots
can be found in Figure 4.3. The average rate of false positives is computed across
each of the 41 null pathways per test. Boxplots of these error rates across the 100
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k h 1 2 · · · 10 11 · · · 25 · · · 29 30 · · · 45 46 47 · · · 70
1 1 1 0 · · · 1 0 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
2 1 1 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
3 1 1 0 · · · 0 0 · · · 0 · · · 1 0 · · · 0 0 0 · · · 0
4 1 1 0 · · · 1 0 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
5 2 0 1 · · · 0 1 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
6 2 0 1 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
7 2 0 1 · · · 0 1 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0



















36 9 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 0 · · · 0
37 0 0 0 · · · 0 0 · · · 1 · · · 0 1 · · · 0 0 0 · · · 0
38 0 0 0 · · · 0 0 · · · 0 · · · 0 1 · · · 0 0 0 · · · 0
39 0 0 0 · · · 0 0 · · · 0 · · · 0 1 · · · 0 0 0 · · · 0



















99 0 0 0 · · · 0 0 · · · 1 · · · 0 0 · · · 1 0 0 · · · 0
100 0 0 0 · · · 0 0 · · · 1 · · · 0 0 · · · 1 0 0 · · · 0
101 0 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 1 0 · · · 0
102 0 0 0 · · · 1 0 · · · 0 · · · 0 0 · · · 0 1 0 · · · 0
103 0 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 1 0 · · · 0
104 0 0 0 · · · 0 0 · · · 0 · · · 1 0 · · · 0 1 0 · · · 0
105 0 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 1 · · · 0
106 0 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 1 · · · 0
107 0 0 0 · · · 0 0 · · · 0 · · · 0 0 · · · 0 0 1 · · · 0



















152 0 0 0 · · · 1 0 · · · 1 · · · 0 0 · · · 0 0 0 · · · 0



















200 0 0 0 · · · 0 1 · · · 0 · · · 0 0 · · · 0 0 0 · · · 1
NMk 4 4 · · · 4 4 · · · 4 · · · 4 4 · · · 4 4 4 · · · 4
Table 4.5: This matrix represents an example mkp matrix for 200 metabolites (rows) and
70 pathways (columns) with pathway size NMk = 4. The metabolite number, k, and
the distribution from which it was drawn, h ∈ (0, 1, . . . , 9), are listed to the left of the
indicator matrix.
102
simulated data sets are presented in Figures 4.6 and 4.7. That is, one point on the
boxplot represents the average error rate for that test in one simulated dataset.
Univariate, Gene ●Univariate, Metabolite Univariate, Naive
*Fisher's Method Multivariate Test
Figure 4.3: The symbol key for Figures 4.4 – 4.7.
Looking at the univariate tests in Figure 4.4 (univariate gene, blue square; uni-
variate metabolite, purple circle) we see the behavior that we would expect for the
different test styles. The tests are able to detect pathways 1–9 according to their
enrichment. Genes but not metabolites are detected for pathways 4–6. Metabolites
but not genes are detected for pathways 7–9 but not perfectly in the competitive
Fisher’s exact and logistic regression tests (panels A and B). This is likely due to the
small pathway size, NMp = 4 in this simulation. In fact the Fisher’s exact test loses
all ability to detect metabolite enrichment beyond 100% enrichment. The logistic
regression model has about 50% detection of the metabolite pathways when they are
50% enriched, pathways 10–12 and 16–18. This distinction is likely due to the loss of
information in the Fisher’s exact test due to dichotomization of genes and metabo-
lites as differential or not. The logistic regression model does not require this and can
make use of even marginal effect sizes. The self-contained sum-of-squared statistic
(panel C) test only begins to have trouble detecting the metabolite enrichment at
25% enrichment, pathways 19-21.
When we turn our attention to the multivariate methods we see that the mul-
tivariate tests (red diamonds) show a similar pattern to the results from p-values
combined by p-value sum (i.e., Fisher’s method; black stars). For the competitive
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C. Sum of Squared Statistics
Figure 4.4: Simulation results for 1000 genes and 200 metabolites generated for 30 sam-
ples. Seventy pathways are assumed with pathways 31–70 representing null pathways.
The correlation values are ρGG = ρMM = 0.20, and ρMG = 0.10. Four metabolites
and 20 genes are included in each pathway. The symbols represent the frequency of
rejecting the null hypothesis in 100 simulated datasets. The symbol key can be found
in Figure 4.3.
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tests these two methods tend to follow the gene expression data results. There is
some improvement in the metabolite only pathways number 16–18. For the logis-
tic regression test they also show a moderate effect, between that of the gene and
metabolite only tests for pathways 19-24 (panel B). All methods appear to perform
maximally in the self-contained sum-of-squared statistics test. Increased power is
even provided to pathways 19-21 (panel C).
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C. Sum of Squared Statistics
Figure 4.5: Simulation results for 1000 genes and 1000 metabolites generated for 30
samples. Seventy pathways are assumed with pathways 31–70 representing null path-
ways. The correlation values are ρGG = ρMM = 0.20, and ρMG = 0.10. Each pathway
includes 20 metabolites and 20 genes. The symbols represent the frequency of rejecting
the null hypothesis in 100 simulated datasets. The symbol key can be found in Figure
4.3.
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In Figure 4.5 the metabolites now have large pathway memberships, NMp = 20,
to be more comparable to the gene pahtways of size NGp = 20. The metabolite
intensities are still generated with lower effect size than the gene expression values.
What stands out in this figure are the orange triangles representing the concatenated
data. In Figure 4.4 the Ngene = 1000 dataset dominated the Nmetabolite = 200 dataset
in the concatenated list. This is noticable by the orange triangles closely following
the pattern of the blue squares of the gene-only analysis. However, in Figure 4.5,
Ngene = Nmetabolite = 1000 so the concatenated list is showing more mixed results.
For the Fisher’s exact test (panel A) the strength of a single enriched platform gets
muddied by the non-enriched platform as in the gene-only and metabolite-only path-
ways numbered 13–18. Additionally, the pathway detection frequency is improved
for the 25% enrichment pathways numbered 19-21, showing rates exceeding either
single platform method. For the logistic regression tests (panel B) the concatenated
data is still more closely related to the gene expression data. This is likely due to
the higher effect sizes of the gene expression data compared to the metabolite data.
The other combined p-values (black star) and 2-df Wald test (red diamond, panel
B) appear to be improved for the low enrichment case of 25% enrichment for genes
and metabolites, pathways 19-21. This shows that the joint enrichment methods are
useful in these marginal cases.
The sum-of-squared statistics test (panel C) continues to perform maximally for
all tests. One other distinction between this self-contained method and the two
competitive tests (panels A and B) can be seen in pathways 25–29. These five
pathways were determined by random selection. Given that 12% of the genes and
metabolites are simulated to be differential in the full dataset these five pathways
will have 12% enrichment on average. These pathways are not detected by the
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competitive tests because the null hypothesis for the competitive test can be written
as Hcomp0 : S has as many differential genes as if they were drawn by chance from the
set of all genes, S ∪ S ′.
To ensure that our power gains are real we must also look at the error rate of
these tests. Figures 4.6 and 4.7 are the corresponding error plots for Figures 4.4 and
4.5. The boxplots reflect 100 estimates of the average error rate across all 41 null
pathways. The striking feature of both plots is the high error rates for the näıve
concatenation of the data when using the Fisher’s exact test (panel A). This error
comes from a high rate of depletion calls. In essence these pathways are detected as
having too few differential elements. This problem is amplified when the pathway
size increases as in Figure 4.7. Given that there are now 40 elements per pathway in
the concatenated list, zero differential elements is significantly smaller than the 12%
expected by random selection.
The combined p-values also show inflated error rates for the competitive tests
(panels A and B) when the larger pathway size is considered, NMp = 20. This may
also be a symptom of detecting depleted pathways. Recall that in these competitive
tests the sample size for the test is based on the number of elements. The larger
pathway size may offer stronger depletion results that are then amplified by the
joining of the two tests.
We do not observe error inflation in the sum-of-squares statistic methods (panels
C). Firstly, the p-value is calculated for a one-sided test. Thus, as currently defined,
the sum of squares test cannot detect depletion. Second, the p-values are determined
by permutation so there is a limit on the level of precision for the p-values which
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C. Sum of Squared Statistics
Figure 4.6: Type I error associated with Figure 4.4. Each boxplot represents 100 measure-
ments of the error rate across the 41 null pathways.
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C. Sum of Squared Statistics
Figure 4.7: Type I error associated with Figure 4.5. Each boxplot represents 100 measure-
ments of the error rate across the 41 null pathways.
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4.5.2 Disjoint pathway simulation results
Now that we have the general pattern of operation for each of these methods let
us explore some specific hypotheses using the disjoint simulations of Section 4.4.1.
Recall that in these simulations we generate data for 50 disjoint pathways, of which
10 are designed to be enriched. The correlation structure is homogeneous in that
each pathway has the same structure. However, there is no correlation simulated
between pathways.
Here we use a different metric to assess the results of the methods. Specifically,
we ask, if we were to choose the top ten pathways by ranking p-values, would we
select the 10 associated pathways? Instead of looking at frequencies of being in the
top 10 we consider the sum of the ranks for the 10 associated pathways. When the
10 associated pathways form the top 10 pathways selected the sum of the ranks is
R =
∑10
x=1 x = 55. When there is no association between the pathway and disease
then the 10 pathways of interest should have a sum of the ranks distributed as
R ∼ Unif(55, 455) and we would thus expect R to fall near E(R) = 255.
Under the null model of no enrichment, that is d1 = d0 = c1 = c0 = 0, the rank
sum of the associated pathways fall nicely around E(R) = 255; see Figure 4.8. Under
the null model of uniform enrichment, that is d1 = d0 = c1 = c0 = δ we also see that
the rank sum of the associated pathways matches E(R) = 255 when δ = 0.05 as in
Figure 4.9 and when δ = 0.10 (data not shown).
To get a better understanding of the methods under specific scenarios we now
consider some non-null simulations. For reference we begin with Figure 4.10. This
simulation assumes that on average 25% of the elements in the associated pathways
are differential, that is d1 = c1 = 0.25 and d0 = c0 = 0. This results in a 5% rate of
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Figure 4.8: The sum of the ranks of the 10 associated pathways assuming no differential
elements were measured, that is d1 = d0 = c1 = c0 = 0. The correlation structure
ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of the 50 disjoint pathway were
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Figure 4.9: The sum of the ranks of the 10 associated pathways assuming a constant
probability of differential elements across the pathways measured, that is d1 =
d0 = c1 = c0 = 0.05. The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is
assumed. Each of the 50 disjoint pathway were simulated to contain 20 metabolites
and 20 genes. Nsample = 30.
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R, achieves nearly perfect rank sums for all tests. In the competitive tests we see
improvement in R when any of the joint tests are used compared to the univariate
gene or metabolite tests.
Under the higher correlation model shown in Figure 4.11, R is larger in the com-
petitive tests compared to the lower correlation model of Figure 4.10. The loss of
power is possibly due to loss of information attributed to the dependent measure-
ments. However, it is not likely that such high correlations will be homogenously
present in real applications [9, 66].
We next consider the behavior of the test in a scenario of few differential elements;
see Figure 4.12. Here we set d1 = c1 = 0.1 and d0 = c0 = 0. The overall enrichment
is 2% on average so the competitive tests still perform better than if the pathways
were randomly assigned. Since d1 and c1 are probabilities we expect that on average
10% of the elements of the associated pathways are differential. It may be the case
that one, or none of the elements are simulated to be differential. These low counts
likely contribute to the increase in R for the sum-of-squared statistics in Figure 4.12.
Finally, we consider the model where d1 = c1 = 0.25 but d0 = c0 = 0.05, that
is we simulate noise in the null pathways; see figure 4.13. It is in this scenario
that the sum-of-squared statistic begins to falter. In fact we see that, beyond an
increase in R, under this scenario the joint enrichment test performs more poorly
than the univariate tests of the gene or metabolites alone. It is not surprising that
this self-contained test performs poorly as this non-specific behavior is a criticism of
self-contained method. It is surprising, however, that the joint methods appear to
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Figure 4.10: The sum of the ranks of the 10 associated pathways assuming 25% of the
elements are differential in these pathways, that is d1 = c1 = 0.25 and d0 = c0 = 0.
The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of the 50
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Figure 4.11: The sum of the ranks of the 10 associated pathways assuming 25% of the
elements are differential in these pathways, that is d1 = c1 = 0.25 and d0 = c0 = 0.
The correlation structure ρGG = ρMM = 0.60, ρMG = 0.25 is assumed. Each of the 50
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Figure 4.12: The sum of the ranks of the 10 associated pathways assuming 10% of the
elements are differential in these pathways, that is d1 = c1 = 0.10 and d0 = c0 = 0.
The correlation structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of the 50
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Figure 4.13: The sum of the ranks of the 10 associated pathways assuming 25% of the
elements are differential in these pathways, that is d1 = c1 = 0.25 and 5% of the
elements are differential in the remaining pathways, d0 = c0 = 0.05. The correlation
structure ρGG = ρMM = 0.20, ρMG = 0.1 is assumed. Each of the 50 disjoint pathway
were simulated to contain 20 metabolites and 20 genes. Nsample = 30.
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4.6 Application to prostate metabolomics and transcriptomic data
We apply these enrichment methods to the metabolomic data of Sreekumar et
al. (2009) [60] and the gene expression data from the same samples (unpublished).
There are 40 samples in this dataset; 16 adjacent benign prostate tissue, 12 localized
prostate tumors, and 12 metastatic prostate tumors. We consider the comparison
between localized tumor and benign tissues. We use the Kyoto Encyclopedia of Genes
and Genomes (KEGG, version 50, April 2009) to determine the pathway mapping.
Of 518 well measured metabolites, there are 147 metabolites that are named and
can be mapped to the KEGG pathways. Of the over 40,000 gene probes measured
on the Agilent Whole Human Genome microarray, there are 2169 genes that can be
mapped to KEGG. To prevent overcounting, probes representing the same gene are
averaged so that each gene is represented only once. There are 98 pathways in which
at least one gene and one metabolite are measured; see Appendix A.
Each of the enrichment methods is run on this data. As this is experimental data,
we do not know the true association of the genes and metabolites with the KEGG
pathways. To assess our results we compare the findings of each method. Figure 4.14
shows a selection of these comparisons. Here we consider the number of pathways
detected to be enriched at p < 0.05 using the logistic regression model. Additionally
the 15 pathways selected by at least one enrichment test are listed in Table 4.6.
Besides significance of the enrichment test (Y/N) the rank of the pathway by each
test is given in parentheses.
Considering the Venn diagrams of Figure 4.14 we see that only combining p-
values via p-value summation (i.e., Fisher’s method; panel ii) detects a pathway not










































Figure 4.14: Venn diagrams comparing enrichment methods Panels i, ii, and iii compare
the univariate methods to each of the joint enrichment tests for the logistic regression
model; (i) Univariate näıve, (ii) p-value sum, (iii) 2-df Wald test. Panel iv compares
the three joint tests.
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Table 4.6: The pathways identified by enrichment testing These 15 pathways were identified
by at least one of the five enrichment tests run on the logistic regression analysis with
the threshold α ≤ 0.05. The pathway ranks are presented in parentheses. The number
of metabolites NMp and genes NGp measured per pathway are provided for reference.
Pathway NMp NGp M G M +G P-sum 2-DF
ABC transporters 4 60 Y (1) N (15) N (67) Y (4) Y (4)
Neuroactive ligand-receptor 2 4 Y (2) Y (1) Y (2) Y (1) Y (1)
interaction
Nitrogen metabolism 12 140 Y (3) N (85) N (43) N (13) N (11)
Aminoacyl-tRNA biosynthesis 6 9 Y (4) N (67) N (36) N (12) N (13)
Arginine and proline metabolism 5 22 Y (5) N (19) N (8) Y (8) Y (8)
Autoimmune thyroid disease 1 40 N (32) Y (2) Y (1) Y (2) Y (2)
Asthma 1 26 N (73) Y (3) Y (3) Y (5) Y (5)
Biotin metabolism 26 38 N (46) Y (4) N (9) Y (7) Y (6)
Taste transduction 2 43 N (26) Y (6) Y (6) Y (6) Y (7)
Purine metabolism 9 205 N (6) Y (5) Y (4) Y (3) Y (3)
Fc epsilon RI signaling pathway 2 71 N (90) Y (7) Y (5) N (14) N (12)
Renal cell carcinoma 2 67 N (85) Y (8) Y (7) N (18) N (15)
Valine, leucine and isoleucine 11 31 N (98) Y (9) N (14) N (20) N (16)
biosynthesis
Glycerophospholipid metabolism 17 31 N (23) Y (10) N (10) N (10) N (10)
Fatty acid biosynthesis 6 5 N (9) N (11) N (86) Y (9) N (9)
the joint models provide a more refined list of pathways compared to using the
union of the results of the two univariate methods. It may be preferable to consider
those pathways with a significant joint association as preferred candidates for follow-
up. Panel (iv) of Figure 4.14 compares the results of these three joint enrichment
methods. We see that in this situation the sum of the p-values by Fisher’s method
selects nearly the same pathways as the 2-df Wald test. Since we are not assuming
correlation between γ and µ the 2-df Wald test is simply a sum of the univariate Wald
statistics so its behavior should be similar to the sum of −log(pγ) and −log(pµ) as
in the Fisher’s method. The similarity of these methods is also seen in their similar
pathway rankings given in Table 4.6.
Though we do not know the true result enrichment state in these observational
data it is interesting to consider the pathways listed in Table 4.6 according to current
knowledge of prostate cancer. First, in Sreekumar et al. (2009) [60] pathways of
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amino acid metabolism and nitrogen metabolism were identified as enriched. This is
supported by our analysis here with both the nitrogen metabolism and the arginine
and proline metabolism pathways detected by the metabolites alone. Valine, leucine
and isoleucine biosynthesis, another amino acid metabolism pathway, is detected by
the genes only but not by the joint tests.
The Fisher’s exact test methods behaved similarly to the logistic regression tests
shown in Figure 4.14. The sum-of-squared statistics tests were overly liberal identi-
fying over 90% of the pathways as enriched. This implies that there was a high rate
of differential elements throughout the datasets similar to the scenario of Figure 4.13.
Such background noise makes a competitive test the preferred choice of enrichment
test. Additionally this may suggest that the KEGG pathway maps, as applied, may
not accurately capture the co-regulation in the data.
4.7 Conclusion
In this work we have considered the application of two-dimensional set enrichment
testing methods for the joint analysis of transcriptomic and metabolomic datasets.
We consider two novel methods: the logistic regression 2-degree of freedom Wald
test and the 2-dimensional permutation p-value for the sum-of-squared statistics
test. Through simulation we explored the properties of these tests in relation to
their univariate counterparts and two simplistic joining methods, namely data con-
catenation and the Fisher’s method for combining p-values. We find that the joint
tests can improve our ability to detect results that are marginal univariately; see
Figures 4.4 and 4.5. We also find that joint tests improve the ranking of associated
pathways compared to their univariate counterparts; see Figures 4.10 and 4.11.
The various joint methods performed similarly for most simulations. The con-
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catenation of datasets and the Fisher’s method of combining p-values had inflated
error in the competitive test; see Figure 4.7. For the logistic regression test, the 2-df
wald test currently peforms similarly to the Fisher’s method for combining the two
p-values. This is likely due to the assumption that ργµ = 0 in the 2-df test. Non-
zero correlation would have provided a weighted sum in the 2-df test. Though we
were not estimating ργµ to be non-zero, the slightly inflated error rate of the Fisher’s
method test, see Figure 4.7, suggests that the independence assumption may not
always hold. In future work we will continue to explore if and when correlation may
be a contributing factor or if there are other methods for combining the tests in a
weighted fashion either at the level of the test statistic or p-value. Though perhaps
the most commonly known, Fisher’s method for combining p-values is only one of
many methods available [41].
One of the more attractive features of the 2-df Wald test and 2-dimensional per-
mutation test is that they can easily be extended to n-dimensions. This will allow
for the incorporation of multiple omics platforms such as proteomics, genomics, or
gene copy number. The data concatenation and sum of p-values methods can also
be extended, but this may compound their potential error.
CHAPTER V
Conclusions and future work
In this work we have explored three different avenues of omics integration impor-
tant to the area of cancer research; (1) the classification of samples, (2) biomarker
discovery, and (3) systems biology.
In Chapter II we utilized a classification method that allowed us to utilize a differ-
ential list of elements from a prior study to make prognostic or diagnostic predictions
about samples in a current study. We extended the classification method by providing
a testing scenario for the classifier. Though originally motivated by the integration
of in vitro and in vivo gene expression datasets we showed that it can be applicable
across omics platforms as well. We demonstrated our result on the metabolomic
and matched gene expression data of Sreekumar et al. (2009) [60]. We demonstrated
that the gene expression profile could be used to distinguish tissue diagnosis using
metabolomic intensities. Though the diagnosis of cancer in prostatectomy tissues is
not of clinical importance this same method could be used to derive classifiers for
biofluids in which classifiers are difficult to build because the true diagnostic state of
the patient is not fully realized.
In Chapter III we explored the use of p-value weighting to improve the power
of per-metabolite tests of differential intensity. Metabolites have the potential to be
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good biomarkers for screening, tracking disease progression, or for drug targeting [38].
However, metabolite levels can be affected by diurnal rhythms, diet, medications,
and other illnesses leading to noisy data and reduced effect sizes when comparing
populations [38]. We used the gene expression information per-metabolic pathway
to devise pathway-based weights. In this way, metabolites that are involved in a
pathway that is disregulated in its gene expression are given higher importance. With
many publicly available gene expression studies and the robustness of microarray
results we felt that this was an appropriate source of prior information. However,
the simulations were not platform-specific, and the recommendations in the chapter
can be applied to other omics platforms. In the future we would also like to consider
reaction-based models for the weights. A reaction-based approach will allow us
to derive a single weight per metabolite thereby removing the summarization step
currently needed when a metabolite participates in multiple pathways.
Finally, in Chapter IV we adopted a systems biology perspective to search for
sets of genes and metabolites that are coordinately differential. We extended two
univariate set enrichment tests to jointly test the gene expression and metabolite
data results. These tests readily expand to N-dimensions and may provide a means
for simultaneously testing a series of omics platforms. Further work will need to be
done to assess correlations between multiple omics pathways for the logistic regression
model as additional platforms are likely to contribute some redundant information.
Use of the score functions for the logistic regression model may prove helpful here.
Additionally, the simple meta-anaysis approach of the Fisher’s method for combining
p-values showed promise but any anti-conservative tendencies due to correlated tests
will be increased as more tests are added. Thus, going forward, we will consider
other meta-analysis techniques that either account for, or are robust to, correlations
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between tests.
Expanding on the work of this dissertation we see the potential for employing a
Bayesian approach. Hierarchical modelling may be used to assess importance of the
per-metabolite hypotheses from corresponding gene expression results as a Bayesian
corollary to the p-value weighting of Chapter III, lend themselves to hierarchical
modelling. In fact, Genovese et al. (2006) [20] allude to this extension in the future
work section of their paper. Concern arises with the minimal level of correlation
expected in a majority of the gene-metabolite pairs. However, the classificatory
ability of the gene signature on metabolite intensities in Chapter II strengthens the
idea that gene expression data could be used to develop a prior distribution for
the metabolomic data. Additionally, empirical Bayes approaches could possibly be
extended [16] in lieu of a fully Bayesian approach.
Additionally, an interesting experimental design question is whether or not to
assess the various omics on matched samples. Matching samples in a case-control
type comparative analysis certainly has its benefits since we can compare the case to a
measure of itself in a non-diseased state. However, the potential benefits of matching
samples are less obvious in omics integration. Some methods such as correlative
analysis are not possible without matched samples. However, methods such as the
enrichment tests of Chapter IV are less likely to be affected by sample matching since
summary measures of sample differentiation per element, e.g. two-sample t-statistics,
are used at the point of data integration. The variety of simulation models developed





Mapping genes and metabolites in the Kyoto Encyclopedia
of Genes and Genomes (KEGG)
To integrate the datasets we use the pathways maps of the Kyoto Encyclopedia
of Genes and Genomes (KEGG, www.genome.jp/kegg), [34, 36, 35]. These include
metabolic pathways, signalling pathways, and disease associated pathways. KEGG
has 200 pathways that are attributed to Homo sapiens (HSA). The pathway maps
are drawn to reflect the current literature at the time of the build (v. 50, April
2009). Of these, 165 pathways contain at least one compound ID. Gene information
can also be extracted from the pathways. All 200 HSA pathways include at least one
gene.
A.1 Gene mapping
There are 4686 unique geneIDs associated with the HSA pathways. Each gene ID
was associated with a single gene name except for seven that were associated with
two gene names (e.g., MYL10 and alias MYLC2PL). The gene IDs were mapped onto
the gene expression data using gene symbol as the index variable. The gene expres-
sion measures of Varambally et al. (2005) [68] were from an Affymetrix HU133Av2
genechip and the gene symbols were obtained from GEO (Gene Expression Omnibus,
www.ncbi.nlm.nih.gov/geo, August 2009) using the GPL570 platform information
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file. Of the 54675 probes on this array, 9491 probes mapped to a KEGG gene ID.
This translates to 4240 unique KEGG gene IDs represented on the array. Of the
gene IDs represented, 39.8% were represented uniquely (see Table A.1). The remain-
der were measured by multiple probes. The matched gene expression measures for
Sreekumar et al. (2009) [60] (unpublished data) were from an Agilent Whole Human
Genome Oligo Microarray and the gene symbols were obtained from GEO platform
information file number GPL1708 (March 2009). Of the 41675 non-control probes on
this array, 6566 probes mapped to a KEGG gene ID. This translates to 4161 unique
KEGG gene IDs represented on the array. Of the gene IDs represented, 59.9% were
represented uniquely (see Table A.1). The remainder were measured by multiple
probes.
Each of the 200 HSA pathways is represented on the Affymetrix array. The Aglient
array represents 198 of the pathways, excluding only “Fluorobenzoate degradation”
(pathway hsa:00364) and “1,4-Dichlorobenzene degradation” (hsa:00627). In Table
A.2 we consider the number of pathways to which a gene ID contributes to deter-
mine the ammount of overlap between pathways. On each array approximately 82%
of the genes are represented in three pathways at most. However, as almost half
(approximately 45%) of the genes are found in multiple pathways and this may need
attention in pathway based methods.
A.2 Metabolite mapping
There were 3076 unique compound IDs found among the HSA pathways. All
possible naming conventions for the molecule associated with the compound ID were
extracted from its description in KEGG (e.g. cpd:C00001 is named “H2O” or “Wa-
ter”). The compound name was used to map the KEGG compound ID numbers
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onto the metabolomics dataset [60]. The data were merged directly by compound
name and then additional curration was done by hand to resolve inconsistencies
in nomenclature. One hundred and eighty-seven (of 626) compounds were named
in the Sreekumar dataset; the remainder were labeled as unknown. Of these 187
named compounds, 13 were not found in KEGG and 3 were found only in non-
HSA pathways. Eleven metabolites had a KEGG compound ID that was not as-
sociated with any pathway. Approximately 15 metabolites could be mapped only
if either an isomeric form was chosen (e.g. cpd:C00303, Glutamine, is not mapped
whereas cpd:C00064, L-Glutamine, is associated with eight pathways) or an alternate
KEGG ID was used (e.g. cpd:C15571, Catechol (generic), is not mapped whereas
cpd:C00090, Catechol, is mapped). In total 160 named metabolites can be mapped
to at least one HSA pathway in KEGG. For analysis we consider only 147 of these 160
mapped metabolites, excluding 13 because they were poorly measured (see Sreeku-
mar et al, 2009).
The 147 compound IDs map to 100 pathways. Table A.3 shows the number
of pathways in which a compound ID is found. Only 38.8% of the compounds are
represented in a single pathway. As metabolites for one pathway likely feed into other
pathways this should not be surprising. Again, this overlap may need attention in
any pathway based methods.
A.3 Integrative pathway mapping
There are up to 100 pathways for which both gene and metabolite measures are
available. Since we are interested in the integration of gene and metabolite data we
focus our attention on these 100 pathways. As at least 100 pathways are removed
from consideration from the gene list we recalculate the pathway overlap for genes
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(Table A.2) in Table A.4. As expected, the amount of overlap is reduced with a
reduced pathway list.
Considering the 100 metabolite mapped pathways, Table A.5 shows the number
of elements measured in each pathway. Not surprisingly the pathway population
of Table A.5 is driven by the gene expression measures; see Table A.6. There are
multiple metabolite measures made for a majority (75%) of the pathways as well,
see Table A.7. However, this leaves 25 pathways in which only a single metabolite is


















> 5 30 0.7%
Table A.1: Frequency of mutliple probe measures. (i) There are 4240 unique KEGG gene
ID numbers represented by 9491 probes on the Affymetrix HU133Av2 array. (ii) There
are 4161 unique gene ID numbers represented by 6566 probes. One geneID (hsa:6144,



























> 10 84 2.0%
Table A.2: Pathway overlap for genes. (i) Over half (54.5%) of the 4020 unique KEGG gene
ID values on the Affymetrix array contribute to a single pathway. (ii) Over half (55.0%)
of the 4161 unique KEGG gene D values on the Agilent array are associated with a
single pathway. On both platforms, two genes (hsa:5594, MAPK1; hsa:5595, MAPK3)











> 7 9 6.2%
Table A.3: Pathway overlap for metabolites. There are 147 compound ID numbers measured
that can be associated with a KEGG HSA pathway. Less than half (38.8%)of these are
associated with a single pathway, whereas, one metabolite (cpd:C00025, Glutamate) is





















> 7 30 1.3%
Table A.4: Overlap for genes in the pathways shared with metabolites. (i) There are
100 pathways, represented by 2375 genes, shared by the metabolites and genes on the
Affymetrix array. (ii) There are 99 pathways, represented by 2296 genes, shared by the
metabolties and the genes on the Agilent array (pathway hsa:00364, “Fluorobenzoate
degradation” is not represented). A slightly higher percentage of the genes are now
associated with a single pathway (see Table A.2). On both platforms there is now
one gene (hsa:218, ALDH3A1) associated with 16 pathways. The two MAPK genes,





2 – 9 11
10 – 19 19
20 – 29 10
30 – 39 14
40 – 49 10
50 – 75 21












Table A.5: Number of elements measured per pathway. (i) Of the 100 pathways for which
both metabolite and Affymetrix gene expression information are available 89 of have
at least 10 elements. Two pathways contain only two measured elements – a gene and
a metabolite. (ii) Of the 99 pathways for which both metabolite and Agilent gene
expression information are available 86 have at least 10 elements and one pathway
contains only two measured elements. On both platforms there are three pathways with
over 200 elements in each (path:hsa04810, Regulation of actin cytoskeleton ((i) 206, (ii)
205), path:hsa04080, Neuroactive ligand receptor ((i) 263, (ii) 250), and path:hsa05200,




1 – 9 17
10 – 19 16
20 – 29 14
30 – 39 12
40 – 49 15
50 – 74 14












Table A.6: Number of genes measured per pathway. (i) Two pathways contains only a single
measured gene each from the Affymetrix data. (ii) One pathway contains only a single
measured gene from the Agilent data. On both platforms the highly poplulated (> 200
genes) pathways include “Pathways in cancer” (path:hsa05200, (i) 327, (ii) 320), “Neu-
roactive ligand-receptor interaction” (path:hsa04080, (i) 254, (ii) 241), and “Regulation















Table A.7: Number of metabolites measured per pathway. Seventy-five percent of the path-
ways are represented by at least two metabolites with as many as 26 metabolites in one
pathway (path:hsa02010, ABC transporters - General - Homo sapiens).
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APPENDIX B
P-value weighting incorporating gene expression and
metabolite information
The following is an extension of pathway-based weighting that we abandoned because
the type I error rate was substantially inflated compared to the methods presented
in Chapter III. Some results and discussion of this method are provided here for
interested readers. It is assumed that readers are familiar with the material in
Chapter III.
B.1 Introduction
An intriguing idea was presented by Roeder et al. (2007) [54] that uniform p-value
weights be assigned to per-element tests according to an a priori defined grouping.
The twist was that the elements being tested in a group, say k, would be used to
define the weight for the group, say ωk.
Consider a vector of elements E and a series of prior studies A1,A2, . . . ,AK each
of which results in a subset of E being selected, say Ai(E ) for study i. We can
then use results of these prior studies to subset E into disjoint sets, E1,E2, . . . ,EK+1.
To construct disjoint subsets of E Roeder et al. (2007) [54] suggest assigning set
membership based upon a hierarchy of the prior studies. Thus if we assume that
study A1 is most related to the current study then E1 = A1(E ). If study A2 is the
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second most interesting study then E2 = A2(E ) ∩A1(E )c, where the set Sc denotes
the complement of the set S. This subsetting is repeated for each of the prior studies
and the remaining elements of E form the subset EK+1.
Since the prior studies are used only to define the grouping, the weights are derived
from information from the elements of the set. That is for set k the pre-standardized
weight uk = f(TEk), where T Ek is some vector of statistics from set Ek and f(·) > 0 is a
function of that information. This weight component uk is assigned to every element
in Ek, vi = uk for all ei ∈ Ek. Finally the weights are standardized, wi = vi/v̄, where
v̄ = n(E )−1
∑n(E )
i=1 vi so that n(E )
−1 ∑n(E )
i=1 wi = 1.
A potential difficulty for using gene expression results to construct per-metabolite
p-value weights is that the gene expression result could dominate the analysis. That
is, the metabolite p-value may be upweighted or downweighed so heavily that the
significance of the test is determined solely from the weight, e.g. p∗i = pi/wi > 1. A
weighting method in which the metabolites contribute information in the construc-
tion of the weights is therefore appealing.
Using a single gene expression study we could rank the metabolites by gene set
enrichment of the KEGG pathways. That is A1,A2, . . . ,Ak would be a ranked
list of differential gene enriched pathways. Alternatively, we can simply group the
metabolites by pathway and use an average weight across overlapping pathways in
the definition of the per metabolite weight as in Chapter III. For either grouping
scheme, the drawback to using the Roeder et al. (2007) [54] grouped weighting
method is that the number of metabolites in the resulting sets, E1,E2, . . . ,EK+1, is
likely to be low; see Appendix A for the number of measured metabolites per KEGG
pathway in the Sreekumar et al. (2009) [60] metabolite data. The grouped weight
of Roeder et al. (2007) [54] relies on the sieve principle to maintain error control
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and thus must have relatively large set membership; Roeder et al. recommend at
least 20 elements per group. This group size requirement reduces that chance that
a groups weight is dominated by a single element. Thus to utilize grouped weights
in the context of metabolic pathways we propose an estimate for the weights that
utilizes both gene and metabolite information.
B.2 The two-component weight
Prior work by Genovese et al. (2006) [20] used per-element weighting. Essentially
this is a group size of one where the weight is determined solely by the prior data.
The work of Roeder et al. (2007) [54] defines grouped weights using only the current
data to define the weights. Thus we propose a two-component weight. Borrowing
information from related metabolites and prior knowledge from gene expression data
we consider a weight ωk for metabolic pathway k defined as
(B.1) ωk = θkω1k + (1− θk)ω2k
with ω1k representing the metabolic component for pathway k (ω1 ≥ 0) and ω2k
representing the component based on the gene expression analysis (ω2k ≥ 0).
We consider two estimates of the mixing parameter θk ∈ [0, 1]. First we estimate
θ̂k = (η̃k − 1)/ηk for pathway k. Here ηk is the number of metabolites with η̃k
measured. This has the nice property that θ̂k = 0 when η̃k = 1 so that ωk = ω2k
which is the weight of Chapter III. However, the disadvantage to this estimate is
that due to highly transient metabolites, ηk may never achieve η̃k and thus θ̂k will
never be 1. This means that even large pathways that would satisfy the 20 element
minimum of Roeder et al. (2007) [54] will contain gene information in the weights.
The alternative θk considered is θ̂k = 1−|ρk| where |ρk| is the absolute correlation
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between genes and metabolites within pathway k. The advantage of this estimate is
that the gene component, ω2k, will have little effect if the genes are not correlated with
the metabolites. The disadvantage is that ρk is difficult to estimate. Additionally,
pathways with minimal correlation will rely heavily on the metabolic component ω1k
regardless of the size ηk.
Finally, we define the components ω1k and ω2k of Equation B.1 as
ω̂1k = − log10(Pmk )
ω̂2k = − log10(P
g
k )
where Pmk and P
g
k are the p-values from tests of pathway enrichment for metabolites
and gene expression, respectively, in pathway k. In this way, ω1k ≥ 0 captures the
metabolite information in the pathway k and ω2k ≥ 0 captures the gene expression
information in that pathway. A separate ωk is constructed for every pathway k =
1, 2, . . . , K+1 for which there is gene and metabolite data available. Notice that the
weight function A used in Chapter III can be written as ωk = ω2k.
To translate the pathway weight ωk to the per-metabolite weight, say wm, we first
assign an unstandardized weight vm = ωk for each metabolite m within the pathway
k. When a metabolite is present in more than one pathway we can use an average of
the pathway weights such that vm =
∑K
k=1 ω̂kI(m ∈ k)/
∑K
k=1 I(m ∈ k) where I(m ∈
k) is an indicator of association for metabolite m with pathway k. Additionally we
can use a rank-based summary such as the median or upper percentile, as in Chapter
III, to determine vm in cases of overlapping pathways. The standardized weight wm





The condition that wm ≥ 0 for all m = 1, . . . ,M is satisfied by ωk ≥ 0. Finally,
unmapped metabolites are given the weight wm = 1 which gives no adjustment to
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This two-component weighting method was testing using the simulation model
of Section 3.4.1 (Chapter III). Here we simulate disjoint pathways under various
enrichment and correlation conditions. The same four enrichment test are also con-
sidered: a directional hypergeometric test, a binomial test of proportions, a weighted
Kolmogorov-Smirnov test, and a sum of squared test statistics test. Only a subset
of the simulation scenarios presented in Chapter III were run for the two-component
weight models.
Some results are presented here using the same four-panel graphic style of Chapter
III. The two-component weight using the coverage based estimate θ̂k = (η̃k − 1)/ηk
will be labelled weight function “F” and will be colored brown. The two-component
weight using the correlation-based estimate θ̂k = |ρk| will be labelled weight function
“G” and will be colored yellow (notice that the definition used in simulation is
reversed from that described above). Since weight function “G” reduces to weight
function “A”, ωk = − log10(P
g
k ) = ω2k when ρ = 0, we also include this function,
colored green, for comparison.
The primary concern with including a metabolic component in the weighting of
the metabolites is that the test will be biased. Under a null model of no differentially
expressed genes or differential metabolites we find that the coverage-based model (F,
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brown) has error rates is above the nominal level a majority of the time; see Figure
B.1. This is for the scenario of ηk = 3 and η̃k = 10 for all pathways k = 1, . . . , K+ 1.
The correlation-based model (G, yellow) is equivalent to the gene expression p-value
model (A, green) when the correlation is zero. However, it too shows increased error
when the correlation is non-zero. The weight function A (green) has error rates that
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Sum of Squared Statistic
Figure B.1: Type 1 error for per-metabolite tests using a significance threshold of α = 0.05
without multiple testing adjustments. 1000 datasets were simulated assuming within
pathway correlation of 0.2 for each metabolites and genes. Unweighted (Raw) p-values
and the three weight functions (F, θ̂k = (η̃k−1)/ηk, brown; G, θ̂k = |ρ|, yellow; A, θ̂k =
0, green) are depicted with increasing between element correlation, ρ ∈ (0, 0.10, 0.15).
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When we look at a high correlation scenario, as in Figure B.2, we see that the error
rates continue to increase with increasing ρ. Again, the single-component weight (A,
green) maintains lower error rates except for the highest correlation scenario, ρ = 0.5.
We happened to define the correlation-based θ estimate counter-intuitively for the
simulation, θ̂k = |ρk|, such that the gene expression component ω2k is dominant
when the genes and metabolites are not correlated. However, we see here, that as
the correlation increases the amount of contribution of the metabolite component
ω1k increases and so does the bias. Thus this correlation-based θ is clearly not the
best choice for this model.
If we turn our attention to a non-null case we quickly see that the single-component
model (A, green) peforms almost equivalently to the two-component models in these
scenarios; see Figures B.3 and B.4. There is a power gain but this is without cor-
recting for the inflated type I error rates. Should error controlling measures, such as
a Bonferroni correction, be made this power would likely be reduced.
Given these issues we chose to abandon the two-component weights in favor of
a single-component weight. In our simulations we found stable single-component
pathway-based weights based on gene expression that did not dominate the metabolic
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Figure B.2: Type 1 error for per-metabolite tests as in Figure B.1 except that the within pathway
correlation is 0.6 for each metabolites and genes and the between element correlation
is increased as high as 50%; ρ ∈ (0, 0.10, 0.15, 0.25, 0.50). Unweighted (Raw) p-values
and the three weight functions (F, θ̂k = (η̃k − 1)/ηk, brown; G, θ̂k = |ρ|, yellow; A,
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AUC Raw F G A
Mean 86 96 96 97
(SEM) (0.49) (0.17) (0.16) (0.15)
Figure B.3: Average receiver operating characteristic (ROC) curves (n=100) depict the
sensitivity and specificity for each test method and weight function when applied to
per-metabolite tests. Data are simulated assuming within pathway correlation of 0.2
for each metabolites and genes and between element correlation of 0.1. Ten of fifty
pathways were simulated as enriched where differential test statistics have mean of
two and three for metabolites and genes, respectively. The mean area under the curve
(AUC) estimate and associated standard error are provided in the table below each
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AUC Raw F G A
Mean 85 94 95 95
(SEM) (0.62) (0.29) (0.27) (0.24)
Figure B.4: Average receiver operating characteristic (ROC) curves (n=100) as in Figure
B.3 except that data are simulated assuming within pathway correlation of 0.6 for each
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